Teva Pharmaceutical Industries Ltd.

Quarterly Report • Oct 27, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-16174

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

(State or other jurisdiction of incorporation or organization)

Israel Not Applicable (IRS Employer Identification Number)

124 Dvora HaNevi'a St., Tel Aviv, ISRAEL 6944020 (Address of principal executive offices) (Zip code)

+972 (3) 914-8213

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing	TEVA	New York Stock Exchange
one Ordinary Share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of September 30, 2021, the registrant had 1,103,007,168 ordinary shares outstanding.

INDEX

PART I. Financial Statements (unaudited)

Item 1.	Financial Statements (unaudited)	5
	Consolidated Balance Sheets	5
	Consolidated Statements of Income (loss)	6
	Consolidated Statements of Comprehensive Income (loss)	7
	Consolidated statements of changes in equity	8
	Consolidated Statements of Cash Flows	10
	Notes to Consolidated Financial Statements	11
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	48
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	79
Item 4.	Controls and Procedures	79
PART II.	OTHER INFORMATION
Item 1.
	Legal Proceedings	80
	Item 1A. Risk Factors	80
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	80
Item 3.	Defaults Upon Senior Securities	80
Item 4.	Mine Safety Disclosures	80
Item 5.	Other Information	80
Item 6.	Exhibits	81
	Signatures	82

INTRODUCTION AND USE OF CERTAIN TERMS

Unless otherwise indicated, all references to the "Company," "we," "our" and "Teva" refer to Teva Pharmaceutical Industries Limited and its subsidiaries, and references to "revenues" refer to net revenues. References to "U.S. dollars," "dollars," "U.S. \$" and "\$" are to the lawful currency of the United States of America, and references to "NIS" are to new Israeli shekels. References to "ADS(s)" are to Teva's American Depositary Share(s). References to "MS" are to multiple sclerosis. Market data, including both sales and share data, is based on information provided by IQVIA, a provider of market research to the pharmaceutical industry ("IQVIA"), unless otherwise stated. References to "R&D" are to Research and Development, references to "IPR&D" are to in-process R&D, references to "S&M" are to Selling and Marketing and references to "G&A" are to General and Administrative. Some amounts in this report may not add up due to rounding. All percentages have been calculated using unrounded amounts. This report on Form 10-Q contains many of the trademarks and trade names used by Teva in the United States and internationally to distinguish its products and services. Any third-party trademarks mentioned in this report are the property of their respective owners.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical information, this Quarterly Report on Form 10-Q, and the reports and documents incorporated by reference in this Quarterly Report on Form 10-Q, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to:

• our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
• our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
• compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice ("DOJ") criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; and environmental risks;
• other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities (including as a result of potential tax reform in the United States); and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2020, including in the sections captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

PART I — FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED BALANCE SHEETS (U.S. dollars in millions, except for share data) (Unaudited)

		September 30, 2021		December 31, 2020
ASSETS
Current assets:
Cash and cash equivalents	\$	2,045	\$	2,177
Accounts receivables, net of allowance for credit losses of \$119 million and \$126 million as of September 30, 2021
and December 31, 2020		4,046		4,581
Inventories		4,167		4,403
Prepaid expenses		1,066		945
Other current assets		805		710
Assets held for sale		25		189
Total current assets		12,154		13,005
Deferred income taxes		622		695
Other non-current assets		518		538
Property, plant and equipment, net		6,040		6,296
Operating lease right-of-use assets		507		559
Identifiable intangible assets, net		7,832		8,923
Goodwill		20,179		20,624
Total assets	\$	47,851	\$	50,640
LIABILITIES AND EQUITY
Current liabilities:
Short-term debt	\$	2,709	\$	3,188
Sales reserves and allowances		4,241		4,824
Accounts payables		1,514		1,756
Employee-related obligations		555		685
Accrued expenses		2,035		1,780
Other current liabilities		770		933
Total current liabilities		11,825		13,164
Long-term liabilities:
Deferred income taxes		910		964
Other taxes and long-term liabilities		2,203		2,240
Senior notes and loans		21,037		22,731
Operating lease liabilities		425		479
Total long-term liabilities		24,575		26,414
Commitments and contingencies, see note 10
Total liabilities		36,400		39,579
Equity:
Teva shareholders' equity:
Ordinary shares of NIS 0.10 par value per share; September 30, 2021 and December 31, 2020: authorized
2,495 million shares; issued 1,209 million shares and 1,202 million shares, respectively		57		57
Additional paid-in capital		27,529		27,443
Accumulated deficit		(10,370)		(10,946)
Accumulated other comprehensive loss		(2,620)		(2,399)
Treasury shares as of September 30, 2021 and December 31, 2020 — 106 million ordinary shares		(4,128)		(4,128)
		10,467		10,026
Non-controlling interests		984		1,035
Total equity		11,451		11,061
Total liabilities and equity	\$	47,851	\$	50,640

Amounts may not add up due to rounding.

The accompanying notes are an integral part of the financial statements.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (U.S. dollars in millions, except share and per share data) (Unaudited)

		Three months ended September 30,		Nine months ended September 30,
	2021	2020	2021	2020
Net revenues	\$3,887	\$ 3,978	\$11,778	\$12,206
Cost of sales	2,093	2,126	6,234	6,528
Gross profit	1,794	1,852	5,544	5,678
Research and development expenses	222	258	723	704
Selling and marketing expenses	597	605	1,798	1,815
General and administrative expenses	291	279	822	846
Intangible assets impairments	21	509	295	1,278
Goodwill impairment	—	4,628	—	4,628
Other assets impairments, restructuring and other items	62	(98)	227	404
Legal settlements and loss contingencies	3	21	113	10
Other income	(25)	(8)	(73)	(30)
Operating income (loss)	623	(4,342)	1,638	(3,978)
Financial expenses, net	241	117	805	565
Income (loss) before income taxes	382	(4,459)	833	(4,543)
Income taxes (benefit)	76	16	235	(147)
Share in (profits) losses of associated companies, net	5	(136)	(9)	(135)
Net income (loss)	302	(4,340)	608	(4,261)
Net income (loss) attributable to non-controlling interests	11	10	32	(121)
Net income (loss) attributable to Teva	292	(4,349)	576	(4,140)
Earnings (loss) per share attributable to ordinary shareholders:
Basic	\$ 0.26	\$ (3.97) \$	0.52	\$ (3.78)
Diluted	\$ 0.26	\$ (3.97) \$	0.52	\$ (3.78)
Weighted average number of shares (in millions):
Basic	1,103	1,096	1,102	1,095
Diluted	1,109	1,096	1,109	1,095

Amounts may not add up due to rounding.

The accompanying notes are an integral part of the financial statements. 6

TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (U.S. dollars in millions)

(Unaudited)

	Three months ended September 30,		Nine months ended September 30,
	2021	2020	2021	2020
Net income (loss)	\$ 302	\$ (4,340) \$ 608		\$(4,261)
Other comprehensive income (loss), net of tax:
Currency translation adjustment	(195)	70	(325)	(348)
Unrealized gain (loss) from derivative financial instruments, net	7	9	21	46
Unrealized loss on defined benefit plans	1	—	2	—
Total other comprehensive income (loss)	(187)	79	(302)	(302)
Total comprehensive income (loss)	115	(4,261)	306	(4,563)
Comprehensive income (loss) attributable to non-controlling interests	(3)	27	(49)	(92)
Comprehensive income (loss) attributable to Teva	\$ 118	\$ (4,288) \$ 355		\$(4,471)

Amounts may not add up due to rounding.

The accompanying notes are an integral part of the financial statements. 7

TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited)

	Teva shareholders' equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders' equity	Non-controlling interests	Total equity
					(U.S. dollars in millions)
Balance at June 30, 2021	1,209	57	27,503	(10,662)	(2,446)	(4,128)	10,324	987	11,311
Net Income (loss)				292			292	11	302
Other comprehensive income
(loss)					(174)		(174)	(13)	(187)
Issuance of Shares	*	*					*		*
Stock-based compensation
expense			26				26		26
Balance at September 30, 2021	1,209	\$ 57	\$ 27,529	\$ (10,370)	\$ (2,620)	\$(4,128)	\$ 10,467	\$ 984	\$11,451

* Represents an amount less than \$0.5 million.

	Teva shareholders' equity
	Ordinary shares			Retained
	Number of shares (in millions)	Stated value	Additional paid-in capital	earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders' equity	Non-controlling interests	Total equity
					(U.S. dollars in millions)
Balance at June 30, 2020	1,202	57	27,374	(6,747)	(2,703)	(4,128)	13,852	972	14,824
Net Income (loss)				(4,349)			(4,349)	10	(4,340)
Other comprehensive income
(loss)					61		61	18	79
Issuance of Shares	*	*					*		*
Stock-based compensation
expense			29				29		29
Balance at September 30, 2020	1,202	\$ 57	\$ 27,403	\$ (11,096)	\$ (2,643)	\$(4,128)	\$ 9,593	\$ 999	\$10,592

* Represents an amount less than \$0.5 million.

	Teva shareholders' equity
	Ordinary shares Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders' equity	Non-controlling interests	Total equity
					(U.S. dollars in millions)
Balance at December 31, 2020	1,202	57	27,443	(10,946)	(2,399)	(4,128)	10,026	1,035	11,061
Net Income (loss)				576			576	32	608
Other comprehensive income
(loss)					(221)		(221)	(81)	(302)
Issuance of Shares	7	*					*		*
Stock-based compensation
expense			86				86		86
Balance at September 30, 2021	1,209	\$ 57	\$ 27,529	\$ (10,370)	\$ (2,620)	\$(4,128)	\$ 10,467	\$ 984	\$11,451

* Represents an amount less than \$0.5 million.

Amounts may not add up due to rounding. The accompanying notes are an integral part of the financial statements.

	Teva shareholders' equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders' equity	Non-controlling interests	Total equity
					(U.S. dollars in millions)
Balance at December 31, 2019	1,198	56	27,312	(6,956)	(2,312)	(4,128)	13,972	1,091	15,063
Net Income (loss)				(4,140)			(4,140)	(121)	(4,261)
Other comprehensive income
(loss)					(331)		(331)	29	(302)
Issuance of shares	4	*					*		*
Stock-based compensation
expense			91				91		91
Balance at September 30, 2020	1,202	\$ 57	\$ 27,403	\$ (11,096)	\$ (2,643)	\$(4,128)	\$ 9,593	\$ 999	\$10,592

* Represents an amount less than \$0.5 million.

Amounts may not add up due to rounding.

The accompanying notes are an integral part of the financial statements.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in millions) (Unaudited)

		Nine months ended September 30,
Operating activities:	2021	2020
Net income (loss)	\$ 608	\$(4,261)
Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization	1,010	1,162
Impairment of long-lived assets and assets held for sale	401	6,314
Net change in operating assets and liabilities	(1,881)	(1,627)
Deferred income taxes – net and uncertain tax positions	13	(656)
Stock-based compensation	86	91
Net loss (gain) from investments and from sale of long lived assets	109	(232)
Research and development in process	—	40
Other items	(4)	54
Net cash provided by (used in) operating activities	342	885
Investing activities:
Beneficial interest collected in exchange for securitized accounts receivables	1,278	1,102
Purchases of property, plant and equipment	(409)	(402)
Proceeds from sale of business and long lived assets	269	54
Proceeds from sale of investments	172	12
Other investing activities	(33)	(44)
Net cash provided by investing activities	1,277	722
Financing activities:
Repayment of senior notes and loans and other long-term liabilities	(1,475)	(1,871)
Proceeds from short term debt	500	231
Repayment of short term debt	(200)	(116)
Redemption of convertible senior notes	(491)	—
Other financing activities	(5)	(4)
Net cash used in financing activities	(1,671)	(1,760)
Translation adjustment on cash and cash equivalents	(80)	5
Net change in cash and cash equivalents	(132)	(148)
Balance of cash and cash equivalents at beginning of period	2,177	1,975
Balance of cash and cash equivalents at end of period	\$ 2,045	\$ 1,827
Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized accounts receivables	\$ 1,310	\$ 1,055

Amounts may not add up due to rounding The accompanying notes are an integral part of the financial statements.

Note 1 – Basis of presentation:

a. Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all normal and recurring adjustments necessary to fairly state the financial position and results of operations of Teva. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission ("SEC"). The year-end balance sheet data was derived from the audited consolidated financial statements as of December 31, 2020, but not all disclosures required by generally accepted accounting principles in the United States ("U.S. GAAP") are included.

In the process of preparing the consolidated financial statements, management makes estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. The inputs into Teva's judgments and estimates also consider the economic implications of the COVID-19 pandemic on its critical and significant accounting estimates, most significantly in relation to sales, reserves and allowances, IPR&D assets, marketed product rights and goodwill, all of which will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the COVID-19 pandemic and the actions taken to contain or treat it, as well as the economic impact on Teva's employees, third-party manufacturers and suppliers, customers and markets. All estimates made by Teva related to the impact of the COVID-19 pandemic within its financial statements may change in future periods. Actual results could differ from those estimates.

The results of operations for the three and nine months ended September 30, 2021 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain amounts in the consolidated financial statements and associated notes may not add up due to rounding. All percentages have been calculated using unrounded amounts.

b. Significant accounting policies

Recently adopted accounting pronouncements

In March 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)—Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This guidance provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The guidance applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This guidance is effective for all entities as of March 12, 2020 through December 31, 2022. There was no material impact to the Company's consolidated financial statements for the period ended September 30, 2021 as a result of adopting this standard update. The Company has completed negotiations to transform the facility base rate of its securitization program and is continuing to evaluate the potential impact of the replacement of the LIBOR benchmark on its interest rate risk management activities. However, it is not expected to have a material impact on the consolidated financial results of operations, financial position or cash flows.

In December 2019, the FASB issued ASU 2019-12 "Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes" (the "update"). The amendments in this update simplify the accounting for income taxes by removing the following exceptions in ASC 740: (1) exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items; (2) exception to accounting for basis differences for equity method investments when a foreign subsidiary becomes an equity method investment; and (3) exception to accounting for basis differences for a foreign subsidiary when a foreign equity method investment becomes a subsidiary; and (4) exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year.

In addition, the update also simplifies the accounting for income taxes in certain topics as follows: (1) requiring that an entity recognize a franchise tax (or similar tax) that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax; (2) requiring that an entity evaluate when a step up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; (3) specifying that an entity can elect (rather than be required to) allocate the consolidated amount of current and deferred tax expense to a legal entity that is not subject to tax

in its separate financial statements; and (4) requiring that an entity reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. Teva adopted the provisions of this update as of January 1, 2021. Based on the Company's evaluation of the above provisions, the Company notes that items (1) and (4) of this paragraph are not material. The adoption of this guidance did not have a material impact on the Company's consolidated financial results of operations, financial position or cash flows.

Recently issued accounting pronouncements, not yet adopted

In August 2020, the FASB issued ASU 2020-06 "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity's Own Equity (Subtopic 815 – 40)." This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. The amendments to this guidance are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The adoption of this guidance will not have a significant impact on the Company's consolidated financial statements.

NOTE 2 – Certain transactions:

The Company has entered into alliances and other arrangements with third parties to acquire rights to products it does not have, to access markets it does not operate in and to otherwise share development costs or business risks. The Company's most significant agreements of this nature are summarized below.

MODAG

In October 2021, Teva announced a license agreement with MODAG GmbH ("Modag"), that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag's lead compound anle138b and a related compound (sery433). The agreement is subject to regulatory approval. Anle138b was initially developed for the treatment of Multiple System Atrophy (MSA) and Parkinson's disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer's disease. A phase 1b clinical trial is currently being completed. Teva will make an upfront payment subject to regulatory approval and Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to \$80 million, as well as future commercial milestones and royalties.

Alvotech

In August 2020, Teva entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including a proposed biosimilar to Humira®. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. Teva paid an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021 that were recorded as R&D expenses. Additional development and commercial milestone payments of up to \$450 million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. In March 2021, Abbvie sued Alvotech for allegedly misappropriating confidential information relating to Humira®. In October 2021, the federal court dismissed the lawsuit for lack of jurisdiction. In addition, there is pending patent litigation between Abbvie and Alvotech related to Alvotech's proposed biosimilar to Humira®.

Eli Lilly and Alder BioPharmaceuticals

In December 2018, Teva entered into an agreement with Eli Lilly resolving the European Patent Office opposition they had filed against Teva's AJOVY® patents. The settlement agreement with Lilly also resolved Lilly's action to revoke the patent protecting AJOVY in the United Kingdom.

On January 8, 2018, Teva signed a global license agreement with Alder BioPharmaceuticals ("Alder"). The agreement validates Teva's intellectual property and resolves Alder's opposition to Teva's European patent with respect to anti-calcitonin gene-related peptide (CGRP) antibodies, including the withdrawal of Alder's appeal before the European Patent Office. Under the terms of the agreement, Alder received a non-exclusive license to Teva's anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the United States and worldwide, excluding Japan. Teva received a \$25 million upfront payment that was recognized as revenue during the first quarter of 2018, and a \$25 million milestone payment in March 2020 that was recognized as revenue in the first quarter of 2020. The agreement stipulates additional development and commercial milestone payments to Teva of up to \$150 million, as well as future royalties.

AUSTEDO®

On September 19, 2017, Teva entered into a partnership agreement with Nuvelution Pharma, Inc. ("Nuvelution") for development of AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States. There are no further plans in this indication following clinical trial results received in February 2020, which failed to meet their primary endpoints. The partnership agreement was terminated on February 5, 2021.

Otsuka

On May 12, 2017, Teva entered into a license and collaboration agreement with Otsuka Pharmaceutical Co. Ltd. ("Otsuka"), providing Otsuka with an exclusive license to conduct phase 2 and 3 clinical trials for AJOVY in Japan and, if approved, to commercialize the product in Japan. Otsuka paid Teva an upfront payment of \$50 million in consideration for the transaction. Results for these trials were received in January 2020 indicating that primary and secondary endpoints were achieved and that no clinically significant adverse events were observed in subjects. In the third quarter of 2020, Otsuka submitted an application to obtain manufacturing and marketing approval for AJOVY in Japan and, as a result, paid Teva a milestone payment of \$15 million, which was recognized as revenue in the third quarter of 2020. AJOVY was approved in Japan in June 2021 and launched on August 30, 2021. As a result of the launch, Otsuka paid Teva a milestone payment of \$35 million, which was recognized as revenue in the third quarter of 2021. Teva may receive additional milestone payments upon achievement of certain revenue targets. Otsuka will also pay Teva royalties on AJOVY sales in Japan.

Celltrion

In October 2016, Teva and Celltrion, Inc. ("Celltrion") entered into a collaborative agreement to commercialize Truxima® and Herzuma®, two biosimilar products for the U.S. and Canadian markets. Teva paid Celltrion \$160 million, of which Teva received an aggregate credit of \$60 million as of March 31, 2021. Teva and Celltrion share the profit from the commercialization of these products. These two products, Truxima and Herzuma, were approved by the FDA in November and December 2018, respectively and were launched in the United States in November 2019 and March 2020, respectively. No additional milestone payments are expected.

Regeneron

In September 2016, Teva and Regeneron Pharmaceuticals, Inc. ("Regeneron") entered into a collaborative agreement to develop and commercialize Regeneron's pain medication product, fasinumab. Teva and Regeneron share in the global commercial rights to this product (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&D costs of approximately \$1 billion. Teva made an upfront payment of \$250 million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of \$120 million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to \$2,230 million, as well as future royalties. Currently, all non-essential activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA.

MedinCell

In November 2013, Teva entered into an agreement with MedinCell for the development and commercialization of multiple long acting injectable products. The lead product candidate selected was risperidone LAI (TV-46000) suspension for subcutaneous use for the treatment of schizophrenia. In August 2021, the FDA accepted the new drug application ("NDA") for risperidone LAI, based on phase 3 data from two pivotal studies. Teva leads the clinical development and regulatory process and is responsible for commercialization of this product candidate. MedinCell may be eligible for development milestones, and future commercial milestones of up to \$112 million in respect of risperidone LAI. Teva will also pay MedinCell royalties on net sales.

Assets and Liabilities Held For Sale:

Certain assets of Teva's business venture in Japan

Teva operates its business in Japan, which was part of Teva's International Market segment, through a business venture with The Takeda Pharmaceutical Company Limited ("Takeda"), in which Teva owns a 51% stake and Takeda owns the remaining 49%.

In July 2020, Teva and Takeda entered into a purchase agreement with Nichi-Iko to sell the majority of the business venture's generic and operational assets. This transaction was completed on February 1, 2021. The business venture retains its specialty portfolio and other selected generic molecules, pipeline assets authorized generics and long listed products (LLPs).

Until the closing date Teva accounted for the business venture assets and liabilities that were sold, as held for sale and determined that the fair value less cost of sale did not exceed the carrying value, resulting in an impairment charge of \$247 million in other assets impairments, restructuring and other items recognized in 2020 and in the first quarter of 2021.

General

Assets held for sale as of September 30, 2021 include certain manufacturing assets that are expected to be sold within the next year. Assets held for sale as of December 31, 2020 included the Teva-Takeda business venture assets sold during the first quarter of 2021, certain OTC assets sold during the second quarter of 2021 and other manufacturing assets.

The table below summarizes all Teva assets included as held for sale as of September 30, 2021 and December 31, 2020:

		September 30, 2021		December 31, 2020
Inventories		(U.S. \$ in millions) 7		146
Property, plant and equipment, net and others		32		312
Goodwill		13		27
Adjustments of assets held for sale to fair value		(27)		(296)
Total assets of the disposal group classified as held for sale in the
consolidated balance sheets	\$	25	\$	189

NOTE 3 – Revenue from contracts with customers:

Disaggregation of revenue

The following table disaggregates Teva's revenues by major revenue streams. For additional information on disaggregation of revenues, see note 15.

		Three months ended September 30, 2021
	North America	Europe	International Markets	Other activities	Total
			(U.S. \$ in millions)
Sale of goods	1,487	1,197	495	160	3,340
Licensing arrangements	22	11	4	1	38
Distribution	363	§	15	—	378
Other	2	11	15	102	130
	\$ 1,875	\$1,220	\$ 530	\$ 262	\$3,887

§ Represents an amount less than \$1 million.

		Three months ended September 30, 2020
	North America	Europe	International Markets	Other activities	Total
			(U.S. \$ in millions)
Sale of goods	1,660	1,116	478	173	3,427
Licensing arrangements	17	7	2	1	27
Distribution	341	§	9	—	350
Other	(1)	(8)	41	142	174
	\$ 2,017	\$1,116	\$ 529	\$ 316	\$3,978

Total
10,268
106
1,018
387
11,778

§ Represents an amount less than \$1 million.

	Nine months ended September 30, 2020
	North		International	Other
	America	Europe	Markets	activities	Total
			(U.S. \$ in millions)
Sale of goods	4,943	3,487	1,417	561	10,408
Licensing arrangements	59	22	6	3	90
Distribution	1,141	3	21	—	1,165
Other	3	9	138	394	543
	\$ 6,146	\$3,520	\$ 1,582	\$ 957	\$12,206

Variable consideration

Variable consideration mainly includes sales reserves and allowances ("SR&A"), comprised of rebates (including Medicaid and other governmental program discounts), chargebacks, returns and other promotional (including shelf stock adjustments) items. Provisions for prompt payment discounts are netted against accounts receivables.

The Company recognizes these provisions at the time of sale and adjusts them if the actual amounts differ from the estimated provisions.

SR&A to U.S. customers comprised approximately 76% of the Company's total SR&A as of September 30, 2021, with the remaining balance primarily in Canada and Germany. The changes in SR&A for third-party sales for the nine months ended September 30, 2021 and 2020 were as follows:

	Sales Reserves and Allowances
	Reserves included in Accounts Receivable, net	Rebates	Medicaid and other governmental allowances		Chargebacks		Returns	Other	Total reserves included in SR&A			Total
					(U.S. \$ in millions)
Balance at December 31, 2020	\$ 80	\$ 2,054	\$	828	\$	1,108	\$ 686	\$ 148	\$	4,824	\$	4,904
Provisions related to sales made in
current year	285	3,060		617		5,949	207	246		10,079		10,364
Provisions related to sales made in
prior periods		(5) (94)		(46)		(31)	(53)	(25)		(249)		(254)
Credits and payments	(293)	(3,286)		(595)		(5,983)	(265)	(247)		(10,376)		(10,669)
Translation differences	—	(22)		(5)		(4)	(4)	(2)		(37)		(37)
Balance at September 30, 2021	\$ 67	1,712	\$	799	\$	1,039	\$ 571	\$ 120	\$	4,241	\$	4,308

	Reserves included in		Medicaid and other governmental allowances
	Accounts Receivable, net	Rebates			Chargebacks Returns			Other	Total reserves included in SR&A		Total
					(U.S.\$ in millions)
Balance at December 31, 2019	\$ 87	\$ 2,895	\$	1,109	\$	1,342	\$ 637	\$176	\$ 6,159	\$	6,246
Provisions related to sales made in
current year	285	3,649		566		6,268	299	55	10,837		11,122
Provisions related to sales made in
prior periods	—	(192)		(116)		(33)	(11)	2	(350)		(350)
Credits and payments	(298)	(4,224)		(650)		(6,418)	(289)	(79)	(11,660)		(11,958)
Translation differences	—	10		4		2	—	(4)	12		12
Balance at September 30, 2020	\$ 74	\$ 2,138	\$	913	\$	1,161	\$ 636	\$150	\$ 4,998	\$	5,072

NOTE 4 – Inventories:

Inventories, net of reserves, consisted of the following:

	September 30, 2021		December 31, 2020
	(U.S. \$ in millions)
Finished products	\$ 2,089	\$	2,378
Raw and packaging materials	1,285		1,231
Products in process	631		605
Materials in transit and payments on account	161		189
Total	\$ 4,167	\$	4,403

NOTE 5 – Identifiable intangible assets:

Identifiable intangible assets consisted of the following:

	Gross carrying amount net of impairment		Accumulated amortization			Net carrying amount
	September 30, 2021		December 31, 2020	September 30, 2021		December 31, 2020		September 30, 2021		December 31, 2020
				(U.S. \$ in millions)
Product rights	\$ 19,034	\$	19,650	\$ 12,234	\$	12,094	\$	6,800	\$	7,556
Trade names	635		621	226		165		409		456
In process research and development	623		911	—		—		623		911
Total	\$ 20,292	\$	21,182	\$ 12,460	\$	12,259	\$	7,832	\$	8,923

Product rights and trade names

Product rights and trade names are assets presented at amortized cost. Product rights and trade names represent a portfolio of pharmaceutical products from various therapeutic categories from various acquisitions with a weighted average life of approximately 10 years.

Amortization of intangible assets was \$199 million and \$251 million in the three months ended September 30, 2021 and 2020, respectively.

Amortization of intangible assets was \$613 million and \$758 million in the nine months ended September 30, 2021 and 2020, respectively.

IPR&D

Teva's IPR&D are assets that have not yet been approved in major markets. Teva's IPR&D is comprised mainly of various generic products from the Actavis Generics acquisition of \$589 million. IPR&D carries intrinsic risks that the asset might not succeed in advanced phases and may be impaired in future periods.

In the first nine months of 2021, Teva reclassified \$162 million of products from IPR&D to product rights, of which \$123 million were reclassified in connection with lenalidomide (generic equivalent of Revlimid®).

Intangible assets impairments

Impairments of long-lived intangible assets for the three months ended September 30, 2021 and 2020, were \$21 million and \$509 million, respectively.

Impairments in the third quarter of 2020 consisted of:

• (a) IPR&D assets of \$360 million, mainly due to: (i) \$262 million related to lenalidomide (generic equivalent of Revlimid®) due to modified competition assumptions as a result of settlements between the innovator and other generic filers; and (ii) \$96 million related to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States; and
• (b) Identifiable product rights of \$149 million, due to: (i) \$110 million related to a change in the assumptions regarding competition for the expected relaunch of metformin tablets; and (ii) \$39 million mainly related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States.

Impairments of long-lived intangible assets for the nine months ended September 30, 2021 and 2020, were \$295 million and \$1,278 million, respectively.

Impairments in the first nine months of 2021 consisted of:

• (a) Identifiable product rights and trade names of \$209 million due to: (i) \$30 million related to lenalidomide (generic equivalent of Revlimid®), resulting from modified competition assumptions as a result of settlements between the innovator and other generic filers, and (ii) \$179 million, mainly related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States; and
• (b) IPR&D assets of \$86 million, mainly due to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States.

Impairments in the first nine months of 2020 consisted of:

• (a) IPR&D assets of \$708 million, mainly due to: (i) \$262 million related to lenalidomide (generic equivalent of Revlimid®) due to modified competition assumptions as a result of settlements between the innovator and other generic filers; (ii) \$211 million related to AUSTEDO for the treatment of Tourette syndrome in pediatric patients in the United States following clinical trial results, received in February 2020,which failed to meet their primary endpoints; and (iii) \$213 million related to generic pipeline products acquired from Actavis Generics resulting from development progress and changes in other key valuation indications (e.g., market size, competition assumptions, legal landscape, launch date) in the United States; and
• (b) Identifiable product rights of \$570 million, mainly due to: (i) \$271 million related to updated market assumptions regarding price and volume of products acquired from Actavis Generics that are primarily marketed in the United States; (ii) \$165 million in Japan in connection with ongoing regulatory pricing reductions and generic competition; and (iii) \$110 million related to a change in the assumptions regarding competition for the expected relaunch of metformin tablets.

The fair value measurement of the impaired intangible assets in the first nine months of 2021 is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The discount rate applied ranged from 7.25% to 10%. A probability of success factor ranging from 20% to 90% was used in the fair value calculation to reflect inherent regulatory and commercial risk of IPR&D.

NOTE 6 – Goodwill:

The changes in the carrying amount of goodwill for the period ended September 30, 2021 were as follows:

	North America Europe			International Markets (U.S. \$ in millions)		Other	Total
Balance as of December 31, 2020 (1)	\$	6,473	\$9,102	\$	2,362	\$2,687	\$20,624
Changes during the period:
Goodwill reclassified as assets held for sale			(7)			(6)	(13)
Translation differences		—	(388)		(44)		(432)
Balance as of September 30, 2021 (1)	\$	6,473	\$8,707	\$	2,318	\$2,681	\$20,179

(1) Accumulated goodwill impairment as of September 30, 2021 and December 31, 2020 was approximately \$25.6 billion.

Teva operates its business through three reporting segments: North America, Europe and International Markets. Each of these business segments is a reporting unit. Additional reporting units include Teva's production and sale of APIs to third parties ("Teva API") and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. The Teva API and Medis reporting units are included under "Other" in the above table. See note 15 for additional segment information.

Teva determines the fair value of its reporting units using the income approach. The income approach is a forward-looking approach for estimating fair value. Within the income approach, the method used is the discounted cash flow method. Teva starts with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then applies a discount rate to arrive at a net present value amount. Cash flow projections are based on Teva's estimates of revenue growth rates and operating margins, taking into consideration industry and market conditions. The discount rate used is based on the weighted average cost of capital ("WACC"), adjusted for the relevant risk associated with country-specific and business-specific characteristics. If any of these expectations were to vary materially from Teva's assumptions, Teva may record an impairment of goodwill allocated to these reporting units in the future. The current projections related to AUSTEDO are a significant assumption in Teva's future projections. Additionally, certain parts of its business volumes were impacted by the COVID-19 pandemic. Management continues to analyze the expected pace of recovery of volumes and the related impact of the COVID-19 pandemic on Teva's business.

First Quarter Developments

During the first quarter of 2021, management assessed developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount.

Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of March 31, 2021 and, therefore, no quantitative assessment was performed.

Second Quarter Developments

During the second quarter of 2021, Teva completed its long-range planning ("LRP") process. The LRP is part of Teva's internal financial planning and budgeting processes and is discussed and reviewed by Teva's management and its board of directors.

Additionally, Teva conducted a quantitative analysis of all reporting units as part of its annual goodwill impairment test with the assistance of an independent valuation expert. Based on this analysis, no goodwill impairment charge was recorded during the second quarter of 2021. Changes to Teva's current assessment regarding the impact of the COVID-19 pandemic on its projections and its long-term forecast related to AUSTEDO could result in future impairments.

Third Quarter Developments

During the third quarter of 2021, management assessed developments that occurred during the quarter to determine if it was more likely than not that the fair value of any of its reporting units was below its carrying amount.

Based on this assessment, management concluded that it was not more likely than not that the fair value of any of the reporting units was below its carrying value as of September 30, 2021 and, therefore, no quantitative assessment was performed. Changes to Teva's current assessment regarding the impact of the COVID-19 pandemic on its projections and its long-term forecast related to AUSTEDO could result in future impairments.

NOTE 7 – Debt obligations:

a. Short-term debt:

			September 30, December 31,
	Weighted average interest rate as of September 30, 2021	Maturity	2021 (U.S. \$ in millions)	2020
Convertible senior debentures	0.25%	2026	23	514
Revolving Credit Facility(1)	LIBOR+1.75%		300	—
Current maturities of long-term liabilities			2,386	2,674
Total short-term debt			\$ 2,709 \$	3,188

(1) As of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF.

Convertible senior debentures

The principal amount of Teva's 0.25% convertible senior debentures due 2026 was \$23 million as of September 30, 2021 and \$514 million as of December 31, 2020. These convertible senior debentures include a "net share settlement" feature according to which the principal amount will be paid in cash and in case of conversion, only the residual conversion value above the principal amount will be paid in Teva shares. Due to the "net share settlement" feature, exercisable at any time, these convertible senior debentures are classified in the Balance Sheet under short-term debt. Holders of the convertible senior debentures exercised their optional repurchase right and redeemed \$491 million of the convertible senior debentures on February 1, 2021, which was the date to exercise this right.

b. Long-term debt:

	Weighted average interest rate as of September 30, 2021	Maturity		December 31, 2020
			2021	(U.S. \$ in millions)
Senior notes EUR 1,500 million	1.13%	2024	1,735	1,839
Senior notes EUR 1,300 million	1.25%	2023	1,505	1,595
Senior notes EUR 1,000 million	6.00%	2025	1,160	1,230
Senior notes EUR 900 million	4.50%	2025	1,044	1,107
Senior notes EUR 750 million	1.63%	2028	864	916
Senior notes EUR 700 million	3.25%	2022	812	861
Senior notes EUR 700 million	1.88%	2027	810	860
Senior notes USD 3,500 million	3.15%	2026	3,495	3,495
Senior notes USD 1,475 million (1)	2.20%	2021	—	1,472
Senior notes USD 3,000 million	2.80%	2023	2,997	2,996
Senior notes USD 2,000 million	4.10%	2046	1,986	1,986
Senior notes USD 1,250 million	6.00%	2024	1,250	1,250
Senior notes USD 1,250 million	6.75%	2028	1,250	1,250
Senior notes USD 1,000 million	7.13%	2025	1,000	1,000

Senior notes USD 844 million	2.95%	2022	851	853
Senior notes USD 789 million	6.15%	2036	783	783
Senior notes USD 613 million	3.65%	2021	614	616
Senior notes USD 588 million	3.65%	2021	586	586
Senior notes CHF 350 million	0.50%	2022	374	397
Senior notes CHF 350 million	1.00%	2025	375	398
Total senior notes			23,491	25,490
Other long-term debt	1.23%	2026	2	1
Less current maturities			(2,386)	(2,674)
Less debt issuance costs			(69)	(86)
Total senior notes and loans			\$21,037	\$22,731

(1) In July 2021, Teva repaid \$1,475 million of its 2.2% senior notes at maturity.

Long-term debt was issued by several indirect wholly-owned subsidiaries of the Company and is fully and unconditionally guaranteed by the Company as to payment of all principal, interest, discount and additional amounts, if any.

Long-term debt as of September 30, 2021 is effectively denominated in the following currencies: 64% in U.S. dollar, 34% in euro and 2% in Swiss franc.

Teva's principal sources of short-term liquidity are its cash on hand, existing cash investments, liquid securities and available credit facilities, primarily its \$2.3 billion unsecured syndicated revolving credit facility entered into in April 2019 ("RCF").

The RCF agreement provides for two separate tranches, a \$1.15 billion tranche A and a \$1.15 billion tranche B. Tranche A had a maturity date of April 8, 2022, of which an amount of \$1.065 billion was extended twice, initially to April 8, 2023 and then to April 8, 2024. Tranche B has a maturity date of April 8, 2024. Loans and letters of credit will be available from time to time under each tranche for Teva's general corporate purposes.

The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time. The net debt to EBITDA ratio limit is 5.00x in the third and fourth quarters of 2021, gradually declines to 4.50x in the first and second quarters of 2022, and continues to gradually decline over the remaining term of the RCF to 3.50x in the first quarter of 2023.

The RCF can be used for general corporate purposes, including repaying existing debt. As of September 30, 2021, \$300 million was outstanding under the RCF. As of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF. Based on current and forecasted results, the Company expects that it will not exceed the financial covenant thresholds set forth in the RCF within one year from the date these financial statements are issued.

Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, the Company will not be able to borrow under the RCF. Additionally, violations of the covenants, under the above-mentioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes is outstanding, could lead to an event of default under the Company's senior notes due to cross acceleration provisions.

Teva expects that it will continue to have sufficient cash resources to support its debt service payments and all other financial obligations within one year from the date that these financial statements are issued.

NOTE 8 – Derivative instruments and hedging activities:

a. Foreign exchange risk management:

In the first nine months of 2021, approximately 48% of Teva's revenues were denominated in currencies other than the U.S. dollar. As a result, Teva is subject to significant foreign currency risks.

The Company enters into forward exchange contracts, purchases and writes options in order to hedge the currency exposure on balance sheet items, revenues and expenses. In addition, the Company takes measures to reduce exposure by using natural hedging. The Company also acts to offset risks in opposite directions among the subsidiaries within Teva. The currency hedged items are usually denominated in the following main currencies: the euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar, the Polish zloty, the Indian rupee and other European and Latin American currencies. Depending on market conditions, foreign currency risk is also managed through the use of foreign currency debt.

The Company may choose to hedge against possible fluctuations in foreign subsidiaries net assets ("net investment hedge") and entered into cross currency swaps and forward contracts in the past in order to hedge such an exposure.

Most of the counterparties to the derivatives are major banks and the Company is monitoring the associated inherent credit risks. The Company does not enter into derivative transactions for trading purposes.

b. Interest risk management:

The Company raises capital through various debt instruments, including straight notes that bear a fixed or variable interest rate, bank loans and convertible debentures. In some cases, the Company has swapped from a fixed to a floating interest rate ("fair value hedge") and from a fixed to a fixed interest rate with an exchange from a currency other than the functional currency ("cash flow hedge"), thereby reducing overall interest expenses or hedging risks associated with interest rate fluctuations.

c. Derivative instruments outstanding:

The following table summarizes the classification and fair values of derivative instruments:

		Fair value Not designated as hedging instruments
		September 30,
		December 31, 2021
Reported under		2020 (U.S. \$ in millions)
Asset derivatives:
Other current assets:
Option and forward contracts	\$	45	\$	24
Liability derivatives:
Other current liabilities:
Option and forward contracts		(23)		(79)

The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives designated in fair value or cash flow hedging relationships:

		Financial expenses, net Three months ended,				Other comprehensive income (loss) Three months ended,
	September 30, September 30, 2021 2020				September 30, 2021		September 30, 2020
Reported under					(U.S. \$ in millions)
Line items in which effects of hedges are
recorded	\$	241	\$	117	\$	(187)	\$	79
Cross-currency swaps—net investment hedge (1)		—		—		—		—

			Financial expenses, net			Other comprehensive income (loss)
		Nine months ended,				Nine months ended,
	September 30, September 30, 2021 2020			September 30, 2021		September 30, 2020
Reported under					(U.S. \$ in millions)
Line items in which effects of hedges are
recorded	\$	805	\$	565	\$	(302)	\$	(302)
Cross-currency swaps—net investment hedge
(1)		—		(2)		—		(21)

The table below provides information regarding the location and amount of pre-tax (gains) losses from derivatives not designated as hedging instruments:

	Financial expenses, net				Net revenues
	Three months ended,				Three months ended,
	September 30, September 30, 2021 2020		September 30, 2021	September 30, 2020
Reported under	(U.S. \$ in millions)
Line items in which effects of hedges are recorded	\$ 241	\$	117	\$	(3,887)	\$	(3,978)
Option and forward contracts (2)	(9)		40		—		—
Option and forward contracts economic hedge (3)	—		—		(16)		3

Notes to Consolidated Financial Statements

(Unaudited)

	Financial expenses, net				Net revenues
	Nine months ended,					Nine months ended,
	September 30, September 30, 2021 2020			September 30, 2021		September 30, 2020
Reported under	(U.S. \$ in millions)
Line items in which effects of hedges are recorded	\$	805	\$	565	\$	(11,778)	\$	(12,206)
Option and forward contracts (2)		(51)		78		—		—
Option and forward contracts economic hedge (3)		—		—		(29)		(37)

• (1) In each of the first and second quarters of 2017, Teva entered into a cross currency swap agreement with a notional amount of \$500 million maturing in 2020. These cross currency swaps were designated as a net investment hedge of Teva's foreign subsidiaries euro denominated net assets, in order to reduce the risk of adverse exchange rate fluctuations. With respect to these cross currency swap agreements, Teva recognized gains which mainly reflect the differences between the float-for-float interest rates paid and received. In the first quarter of 2020, these crosscurrency swap agreements expired. The settlement of these transactions resulted in cash proceeds of \$3 million.
• (2) Teva uses foreign exchange contracts (mainly option and forward contracts) to hedge balance sheet items from currency exposure. These foreign exchange contracts are not designated as hedging instruments for accounting purposes. In connection with these foreign exchange contracts, Teva recognizes gains or losses that offset the revaluation of the balance sheet items also recorded under financial expenses, net.
• (3) Teva entered into option and forward contracts designed to limit the exposure of foreign exchange fluctuations on projected revenues and expenses recorded in euro, the Swiss franc, the Japanese yen, the British pound, the Russian ruble, the Canadian dollar and some other currencies to protect its projected operating results for 2021 and 2022. These derivative instruments do not meet the criteria for hedge accounting, however, they are accounted for as an economic hedge. These derivative instruments, which may include hedging transactions against future projected revenues and expenses, are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. In 2020, Teva recognized a loss of \$27 million in relation with the 2021 hedging program Teva entered into in the second half of 2020. In the first nine months of 2021, the positive impact from these derivatives recognized under revenues was \$29 million, of which \$6 million relate to 2022 operating results. Changes in the fair value of the derivative instruments are recognized in the same line item in the statements of income as the underlying exposure being hedged. The cash flows associated with these derivatives are reflected as cash flows from operating activities in the consolidated statements of cash flows.

d. Amortizations due to terminated derivative instruments:

Forward starting interest rate swaps and treasury lock agreements

In 2015, Teva entered into forward starting interest rate swaps and treasury lock agreements to protect the Company from interest rate fluctuations in connection with a future debt issuance the Company was planning. These forward starting interest rate swaps and treasury lock agreements were terminated in July 2016 upon the debt issuance. The termination of these transactions resulted in a loss position of \$493 million, which was recorded in other comprehensive income (loss) and is amortized under financial expenses, net over the life of the debt.

With respect to these forward starting interest rate swaps and treasury lock agreements, losses of \$8 million were recognized under financial expenses, net for each of the three months ended September 30, 2021 and 2020, respectively, and losses of \$24 million and \$23 million were recognized under financial expenses, net for the nine months ended September 30, 2021 and 2020, respectively.

Fair value hedge

In the third quarter of 2016, Teva terminated interest rate swap agreements designated as a fair value hedge relating to its 2.95% senior notes due 2022 with respect to \$844 million notional amount and its 3.65% senior notes due 2021 with respect to \$450 million notional amount. Settlement of these transactions resulted in a gain position of \$41 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt as additional interest expense.

In the third quarter of 2019, Teva terminated \$500 million interest rate swap agreements designated as a fair value hedge relating to its 2.8% senior notes due 2023 with respect to \$3,000 million notional amount. Settlement of these transactions resulted in cash proceeds of \$10 million. The fair value hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt.

Cash flow hedge

In the fourth quarter of 2019, Teva terminated \$588 million cross-currency swap agreements against its outstanding 3.65% senior notes maturing in November 2021. Settlement of these transactions resulted in cash proceeds of \$95 million. The cash flow hedge accounting adjustments of these instruments, which are recorded under senior notes and loans, are amortized under financial expenses, net over the life of the debt.

With respect to the interest rate swap and cross-currency swap agreements, gains of \$1 million were recognized under financial expenses, net for each of the three months ended September 30, 2021 and 2020, respectively, and gains of \$2 million and \$3 million were recognized under financial expenses, net for the nine months ended September 30, 2021 and 2020, respectively.

NOTE 9 – Legal settlements and loss contingencies:

In the third quarter of 2021, Teva recorded an expense of \$3 million in legal settlements and loss contingencies, compared to \$21 million in the third quarter of 2020. The expense in the third quarter of 2020 was mainly due to settling, in part, antitrust claims challenging a patent settlement agreement, partially offset by proceeds received following a settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics).

In the third quarter of 2021, Teva also recorded a liability and an offsetting insurance receivable related to mediation discussed in note 10, for which there was no net impact to litigation expenses.

In the first nine months of 2021, Teva recorded an expense of \$113 million in legal settlements and loss contingencies, compared to \$10 million in the first nine months of 2020. The expense in the first nine months of 2021 was mainly due to the provision for the carvedilol patent litigation (see note 10). The expense in the first nine months of 2020 was mainly related to an increase of a reserve for certain legal expenses and settlement contributions related to product liability claims in the United States and partially settling antitrust claims challenging a patent settlement agreement, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of an action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics).

As of September 30, 2021 and December 31, 2020, Teva's provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was \$2,009 million and \$1,625 million, respectively.

NOTE 10 – Commitments and contingencies:

General

From time to time, Teva and/or its subsidiaries are subject to claims for damages and/or equitable relief arising in the ordinary course of business. In addition, as described below, in large part as a result of the nature of its business, Teva is frequently subject to litigation. Teva generally believes that it has meritorious defenses to the actions brought against it and vigorously pursues the defense or settlement of each such action.

Teva records a provision in its financial statements to the extent that it concludes that a contingent liability is probable and the amount thereof is estimable. Based upon the status of the cases described below, management's assessments of the likelihood of damages, and the advice of counsel, no provisions have been made regarding the matters disclosed in this note, except as noted below. Litigation outcomes and contingencies are unpredictable, and excessive verdicts can occur. Accordingly, management's assessments involve complex judgments about future events and often rely heavily on estimates and assumptions. Teva continuously reviews the matters described below and may, from time to time, remove previously disclosed matters where the exposures were fully resolved in the prior year, or determined to no longer meet the materiality threshold for disclosure, or were substantially resolved.

If one or more of such proceedings described below were to result in final judgments against Teva, such judgments could be material to its results of operations and cash flows in a given period. In addition, Teva incurs significant legal fees and related expenses in the course of defending its positions even if the facts and circumstances of a particular litigation do not give rise to a provision in the financial statements.

In connection with third-party agreements, Teva may under certain circumstances be required to indemnify, and may be indemnified by, in unspecified amounts, the parties to such agreements against third-party claims. Among other things, Teva's agreements with third parties may require Teva to indemnify them, or require them to indemnify Teva, for the costs and damages incurred in connection with product liability claims, in specified or unspecified amounts.

Except as otherwise noted, all of the litigation matters disclosed below involve claims arising in the United States. Except as otherwise noted, all third party sales figures given below are based on IQVIA (formerly IMS Health Inc.) data.

Intellectual Property Litigation

From time to time, Teva seeks to develop generic versions of patent-protected pharmaceuticals for sale prior to patent expiration in various markets. In the United States, to obtain approval for most generics prior to the expiration of the originator's patents, Teva must challenge the patents under the procedures set forth in the Hatch-Waxman Act of 1984, as amended. To the extent that Teva seeks to utilize such patent challenge procedures, Teva is and expects to be involved in patent litigation regarding the validity, enforceability or infringement of the originator's patents. Teva may also be involved in patent litigation involving the extent to which its product or manufacturing process techniques may infringe other originator or third-party patents.

Additionally, depending upon a complex analysis of a variety of legal and commercial factors, Teva may, in certain circumstances, elect to market a generic version even though litigation is still pending. To the extent Teva elects to proceed in this manner, it could face substantial liability for patent infringement if the final court decision is adverse to Teva, which could be material to its results of operations and cash flows in a given period.

Teva could also be sued for patent infringement outside of the context of the Hatch-Waxman Act. For example, Teva could be sued for patent infringement after commencing sales of a product. In addition, for biosimilar products, Teva could be sued according to the "patent dance" procedures of the Biologics Price Competition and Innovation Act (BPCIA).

The general rule for damages in patent infringement cases in the United States is that the patentee should be compensated by no less than a reasonable royalty and it may also be able, in certain circumstances, to be compensated for its lost profits. The amount of a reasonable royalty award would generally be calculated based on the sales of Teva's product. The amount of lost profits would generally be based on the lost sales of the patentee's product. In addition, the patentee may seek consequential damages as well as enhanced damages of up to three times the profits lost by the patent holder for willful infringement, although courts have typically awarded much lower multiples.

Teva is also involved in litigation regarding patents in other countries where it does business, particularly in Europe. The laws concerning generic pharmaceuticals and patents differ from country to country. Damages for patent infringement in Europe may include lost profits or a reasonable royalty, but enhanced damages for willful infringement are generally not available.

In July 2014, GlaxoSmithKline ("GSK") sued Teva in Delaware federal court for infringement of a patent directed to using carvedilol in a specified manner to decrease the risk of mortality in patients with congestive heart failure. Teva and eight other generic producers began selling their carvedilol tablets (the generic version of GSK's Coreg®) in September 2007. A jury trial was held and the jury returned a verdict in GSK's favor finding Teva liable for induced infringement, including willful infringement, and assessing damages of \$235.5 million, not including pre- or post-judgment interest or a multiplier for willfulness. Thereafter, the judge overturned the jury verdict, finding no induced infringement by Teva and that Teva did not owe any damages. On August 5, 2021, the Court of Appeals for the Federal

Circuit issued a two-to-one decision reinstating the \$235.5 million verdict and finding Teva liable for patent infringement. On October 7, 2021, Teva filed a petition for en banc review with the Court of Appeals for the Federal Circuit. If further appeals are decided against Teva, the case would be remanded to the district court for it to consider Teva's other legal and equitable defenses that have not yet been considered by the district court. In the first quarter of 2021, Teva recognized a provision based on its offer to settle such matter.

Product Liability Litigation

Teva's business inherently exposes it to potential product liability claims. Teva maintains a program of insurance, which may include commercial insurance, self-insurance (including direct risk retention), or a combination of both approaches, in amounts and on terms that it believes are reasonable and prudent in light of its business and related risks. However, Teva sells, and will continue to sell, pharmaceuticals that are not covered by its product liability insurance; in addition, it may be subject to claims for which insurance coverage is denied as well as claims that exceed its policy limits. Product liability coverage for pharmaceutical companies is becoming more expensive and increasingly difficult to obtain. As a result, Teva may not be able to obtain the type and amount of insurance it desires, or any insurance on reasonable terms, in all of its markets.

Teva and its subsidiaries are parties to litigation relating to previously unknown nitrosamine impurities discovered in certain products. The discovery led to a global recall of single and combination valsartan medicines around the world starting in July 2018 and to subsequent recalls on other products. The nitrosamine impurities in valsartan are allegedly found in the active pharmaceutical ingredient (API) supplied by multiple API manufacturers. Teva's products allegedly at issue in the various nitrosamine-related litigations pending in the United States include valsartan, losartan, metformin and ranitidine. There are currently two Multi-District Litigations ("MDL") pending in the United States District Courts against Teva and numerous other manufacturers. One MDL is pending in the United States District Court for the District of New Jersey for valsartan, losartan and irbesartan. Teva is not named in complaints with respect to irbesartan. The second MDL is pending in the United States District Court for the Southern District of Florida for ranitidine. The lawsuits against Teva in the MDLs consist of individual personal injury and/or product liability claims and economic damages claims brought by consumers and end payors on behalf of purported classes of other consumers and end payors as well as medical monitoring class claims. Defendants' motions to dismiss in the valsartan, losartan and irbesartan MDL were denied in part and granted in part. Plaintiffs have moved to file amended complaints, which defendants have opposed. In the ranitidine MDL, the generics manufacturers' motions to dismiss have been granted, although certain plaintiffs have appeals pending. Teva, as well as other generic manufacturers, was also recently named in several state court actions asserting allegations similar to those in the ranitidine MDL. In addition to these MDLs, Teva has also been named in a consolidated proceeding pending in the United States District Court for the District of New Jersey brought by individuals and end payors seeking economic damages on behalf of purported classes of consumers and end payors who purchased Teva's, as well as other generic manufacturers' metformin products. The defendants' motion to dismiss the metformin complaint was granted, and on June 21, 2021, plaintiffs filed an amended complaint. Defendants' motion to dismiss the amended metformin complaint is pending. Teva has also been named in one personal injury metformin case filed in Florida state court, which has been removed to federal court. Similar lawsuits are pending in Canada and Germany.

Competition Matters

As part of its generic pharmaceuticals business, Teva has challenged a number of patents covering branded pharmaceuticals, some of which are among the most widely-prescribed and well-known drugs on the market. Many of Teva's patent challenges have resulted in litigation relating to Teva's attempts to market generic versions of such pharmaceuticals under the federal Hatch-Waxman Act. Some of this litigation has been resolved through settlement agreements in which Teva obtained a license to market a generic version of the drug, often years before the patents expire.

Teva and its subsidiaries have increasingly been named as defendants in cases that allege antitrust violations arising from such settlement agreements. The plaintiffs in these cases, which are usually direct and indirect purchasers of pharmaceutical products, and often assert claims on behalf of classes of all direct and indirect purchasers, typically allege that (1) Teva received something of value from the innovator in exchange for an agreement to delay generic entry, and (2) significant savings could have been realized if there had been no settlement agreement and generic competition had commenced earlier. These class action cases seek various forms of injunctive and monetary relief, including damages based on the difference between the brand price and what the generic price allegedly would have been and disgorgement of profits, which are automatically tripled under the relevant statutes, plus attorneys' fees and costs. The alleged damages generally depend on the size of the branded market and the length of the alleged delay, and can be substantial—potentially measured in multiples of the annual brand sales—particularly where the alleged delays are lengthy or branded drugs with annual sales in the billions of dollars are involved.

Teva believes that its settlement agreements are lawful and serve to increase competition, and has defended them vigorously. In Teva's experience to date, these cases have typically settled for a fraction of the high end of the damages sought, although there can be no assurance that such outcomes will continue.

In June 2013, the U.S. Supreme Court held, in Federal Trade Commission ("FTC") v. Actavis, Inc. (the "AndroGel case"), that a rule of reason test should be applied in analyzing whether such settlements potentially violate the federal antitrust laws. The Supreme Court held that a trial court must analyze each agreement in its entirety in order to determine whether it violates the antitrust laws. This new test has resulted in increased scrutiny of Teva's patent settlements, additional action by the FTC and state and local authorities, and an increased risk of liability in Teva's currently pending antitrust litigations.

In May 2015, Cephalon Inc., a Teva subsidiary ("Cephalon"), entered into a consent decree with the FTC (the "Modafinil Consent Decree") under which the FTC dismissed antitrust claims against Cephalon related to certain finished modafinil products (marketed as PROVIGIL®) in exchange for Cephalon and Teva agreeing to, among other things, abide by certain restrictions and limitations, for a period of ten years, when entering into settlement agreements to resolve patent litigation in the United States. Those restrictions and limitations were further refined in connection with the settlement of other unrelated FTC antitrust lawsuits, as described below, and the term of the Modafinil Consent Decree was extended until 2029.

In November 2020, the European Commission issued a final decision in its proceedings against both Cephalon and Teva, finding that the 2005 settlement agreement between the parties had the object and effect of hindering the entry of generic modafinil, and imposed fines totaling €60.5 million on Teva and Cephalon. Teva and Cephalon filed an appeal against the decision in February 2021. A provision for this matter was included in the financial statements. Teva has provided the European Commission with a bank guarantee in the amount of the imposed fines.

Teva and its affiliates have been named as defendants in lawsuits alleging that multiple patent litigation settlement agreements relating to AndroGel® 1% (testosterone gel) violate the antitrust laws. The first of these lawsuits (the "Georgia AndroGel Litigation") was filed in January 2009 in California federal court, and later transferred to Georgia federal court, with the FTC and the State of California, and later private plaintiffs, challenging a September 2006 patent litigation settlement between Watson Pharmaceuticals, Inc. ("Watson"), from which Teva later acquired certain assets and liabilities, and Solvay Pharmaceuticals, Inc. ("Solvay"). The second lawsuit (the "Philadelphia AndroGel Litigation") was filed by the FTC in September 2014 in federal court in Philadelphia, challenging Teva's December 2011 patent litigation settlement with AbbVie. The FTC stipulated to dismiss Teva from both litigations, in exchange for Teva's agreement to amend the Modafinil Consent Decree, as described above. On July 16, 2018, the direct purchaser plaintiffs' motion for class certification in the Georgia AndroGel Litigation was denied and Teva later settled with the retailer plaintiffs in the Georgia AndroGel Litigation as well as the three direct purchasers that had sought class certification, thus leaving no remaining claims in the Georgia AndroGel Litigation. In August 2019, certain other direct-purchaser plaintiffs (who would have been members of the direct purchaser class in the Georgia AndroGel Litigation, had it been certified) filed their own claims in the federal court in Philadelphia (where the Philadelphia AndroGel Litigation has been pending), challenging (in one complaint) both the September 2006 settlement between Watson and Solvay, and the December 2011 settlement between Teva and AbbVie. Those claims remain pending. Annual sales of AndroGel® 1% were approximately \$350 million at the time of the earlier Watson/Solvay settlement and approximately \$140 million at the time Actavis launched its generic version of AndroGel® 1% in November 2015. A provision for these matters was included in the financial statements.

In December 2011, three groups of plaintiffs sued Wyeth and Teva for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving extended release venlafaxine (generic Effexor XR®) entered into in November 2005. The cases were filed by a purported class of direct purchasers, by a purported class of indirect purchasers and by certain chain pharmacies in the U.S. District Court for the District of New Jersey. The plaintiffs claim that the settlement agreement between Wyeth and Teva unlawfully delayed generic entry. In October 2014, the court granted Teva's motion to dismiss in the direct purchaser cases, after which the parties agreed that the court's reasoning applied equally to the indirect purchaser cases. Plaintiffs appealed and, in August 2017, the Third Circuit reversed the district court's decision and remanded for further proceedings. In March 2020, the district court temporarily stayed discovery and referred the case to mediation, and discovery remains stayed. Annual sales of Effexor XR® were approximately \$2.6 billion at the time of settlement and at the time Teva launched its generic version of Effexor XR® in July 2010.

In February 2012, two purported classes of direct-purchaser plaintiffs sued GSK and Teva in New Jersey federal court for alleged violations of the antitrust laws in connection with their settlement of patent litigation involving lamotrigine (generic Lamictal®) entered into in February 2005. The plaintiffs claim that the settlement agreement unlawfully delayed generic entry and seek unspecified damages. In December 2018, the district court granted the direct-purchaser plaintiffs' motion for class certification, but on April 22, 2020, the Third Circuit reversed that ruling and remanded for further class certification proceedings. On April 9, 2021, the district court denied the direct purchaser plaintiffs' renewed motion for class certification, but allowed additional briefing on whether plaintiffs can still meet the class certification standard on certain of their claims. Annual sales of Lamictal® were approximately \$950 million at the time of the settlement and approximately \$2.3 billion at the time Teva launched its generic version of Lamictal® in July 2008.

In April 2013, purported classes of direct purchasers of, and end payers for, Niaspan® (extended release niacin) sued Teva and Abbott for violating the antitrust laws by entering into a settlement agreement in April 2005, to resolve patent litigation over the product. A multidistrict litigation has been established in the U.S. District Court for the Eastern District of Pennsylvania. Throughout 2015 and in January 2016, several individual direct-purchaser opt-out plaintiffs filed complaints with allegations nearly identical to those of the direct purchasers' class. In August 2019, the district court certified the direct-purchaser class, but in June 2020, the court denied the indirect purchasers' motion for class certification without prejudice. On September 4, 2020, the indirect purchasers filed a renewed motion for class certification, which was subsequently denied with prejudice by the district court and is now on appeal before the Court of Appeals for the Third Circuit. In October 2016, the District Attorney for Orange County, California, filed a similar complaint in California state court, which has since been amended, alleging violations of state law. Defendants moved to strike the District Attorney's claims for restitution and civil penalties to the extent not limited to alleged activity occurring in Orange County. The Superior Court denied that motion. The Court of Appeals subsequently reversed the decision and in June 2020, the California Supreme Court reversed the Court of Appeals' decision, allowing the District Attorney's claims to proceed. Annual sales of Niaspan® were approximately \$416 million at the time of the settlement and approximately \$1.1 billion at the time Teva launched its generic version of Niaspan® in September 2013.

Since January 2014, numerous lawsuits have been filed in the U.S. District Court for the Southern District of New York by purported classes of end-payers for, and direct-purchasers of, Actos® and Actoplus Met (pioglitazone and pioglitazone plus metformin) against Takeda, the innovator, and several generic manufacturers, including Teva, Actavis and Watson. The lawsuits allege, among other things, that the settlement agreements between Takeda and the generic manufacturers violated the antitrust laws. The court dismissed the end-payers' lawsuits against all defendants in September 2015. On February 8, 2017, the Court of Appeals for the Second Circuit affirmed the dismissal in part and vacated and remanded the dismissal in part with respect to the claims against Takeda. The direct purchasers' case had been stayed pending resolution of the appeal in the end payer matter and the direct purchasers amended their complaint for a second time following the Second Circuit's decision, but on October 8, 2019, the district court dismissed, with prejudice, the direct purchasers' claims against the generic manufacturers (including Teva, Actavis, and Watson). At the time of Teva's settlement, annual sales of Actos® and Actoplus Met were approximately \$3.7 billion and approximately \$500 million, respectively. At the time Teva launched its authorized generic version of Actos® and Actoplus Met in August 2012, annual sales of Actos® and Actoplus Met were approximately \$2.8 billion and approximately \$430 million, respectively.

In January 2019, generic manufacturer Cipla Limited filed a lawsuit against Amgen, which was later amended to include Teva as a defendant, in Delaware federal court, alleging, among other things, that a January 2, 2019 settlement agreement between Amgen and Teva, resolving patent litigation over cinacalcet (generic Sensipar®), violated the antitrust laws. On August 14, 2020, Cipla Limited agreed to dismiss its claims against Teva, with prejudice, and those claims have since been dismissed. Putative classes of direct-purchaser and end-payer plaintiffs have also filed antitrust lawsuits (which have since been coordinated in federal court in Delaware) against Amgen and Teva related to the January 2, 2019 settlement. On July 22, 2020, a magistrate judge recommended that plaintiffs' claims be dismissed and on November 30, 2020, the district court overruled the magistrate judge's recommendation, denied Teva's motion to dismiss in part, and instructed plaintiffs to file amended complaints, which plaintiffs filed on February 16, 2021. Teva again moved to dismiss those complaints on March 30, 2021, based on plaintiffs' failure to allege both (a) that the settlement violated the antitrust laws and (b) that the settlement caused any actual injury to plaintiffs, and Teva's motions remain pending. Annual sales of Sensipar® in the United States were approximately \$1.4 billion at the time Teva launched its generic version of Sensipar® in December 2018, and at the time of the January 2, 2019 settlement.

On July 15, 2021, the U.K. Competition and Markets Authority ("CMA") issued a decision imposing fines for breaches of U.K. competition law by Allergan, Actavis UK and Auden Mckenzie and a number of other companies in connection with the supply of 10mg and 20mg hydrocortisone tablets in the U.K. The decision combines the CMA's three prior investigations into the supply of hydrocortisone tablets in the U.K. and encompasses those allegations which were subject to prior statements of objections (a provisional finding of breach of the Competition Act), in particular those under case 50277-1 (unfair pricing, originally subject to a statement of objections on December 16, 2016), case 50277-2 (anti-competitive agreement with AMCo, originally subject to a statement of objections on March 3, 2017) as well as the CMA's subsequent investigation relating to an anti-competitive agreement with Waymade. On January 9, 2017, Teva completed the sale of Actavis UK to Accord Healthcare Limited, in connection with which Teva will indemnify Accord Healthcare for potential fines imposed by the CMA and/or damages awarded by a court against Actavis UK in relation to the December 16, 2016 and March 3, 2017 statements of objections, and resulting from conduct prior to the closing date of the sale. In addition, Teva agreed to indemnify Allergan against losses arising from this matter in the event of any such fines or damages. A provision for the estimated exposure for Teva related to the fines and/or damages has been recorded in the financial statements.

In March 2021, following the 2019 European Commission's inspection of Teva and subsequent request for information, the European Commission opened a formal antitrust investigation to assess whether Teva may have abused a dominant position by delaying the market entry and uptake of medicines that compete with COPAXONE. Annual sales of COPAXONE in the European Economic Area for the past calendar year were approximately \$380 million.

Between September 1, 2020 and December 20, 2020, separate plaintiffs purporting to represent putative classes of direct and indirect purchasers and opt-out retailer purchasers of Bystolic® (nebivolol hydrochloride) filed separate complaints in the U.S. District Court for the Southern District of New York against several generic manufacturers, including Teva, Actavis, and Watson, alleging, among other things, that the settlement agreements these generic manufacturers entered into with Forest Laboratories, Inc., the innovator, to resolve patent litigation over Bystolic® violated the antitrust laws. The cases were coordinated and on March 15, 2021, plaintiffs filed amended complaints, which Teva, Actavis, and Watson have moved to dismiss on the grounds (among others) that the allegations do not plausibly demonstrate any improper payment from Forest to Watson that could create antitrust liability. Those motions remain pending. Annual sales of Bystolic® in the United States were approximately \$700 million at the time of Watson's 2013 settlement with Forest.

In February 2021, the State of New Mexico filed a lawsuit against Teva and certain other defendants related to various medicines used to treat HIV. In September and October 2021, several retailers and a health insurance provider filed similar claims in federal court in the Northern District of California and in the District of Minnesota. As they relate to Teva, the lawsuits challenge settlement agreements Teva entered into with Gilead in 2013 and 2014 to resolve patent litigation relating to Teva's generic versions of Viread®, Truvada®, and Atripla®. Plaintiffs allege that the settlements contain improper reverse payments that delayed the availability of Teva's generic products, in violation of the federal antitrust laws and state law. The claims against Teva in these matters are in preliminary stages. Annual sales in the United States at the time of the settlement of Viread®, Truvada® and Atripla® were approximately \$582 million, \$2.4 billion, and \$2.9 billion, respectively. Annual sales in the United States at the time Teva launched its generic version of Viread® in 2017, Truvada® in 2020 and Atripla® in 2020 were approximately \$728 million, \$2.1 billion and \$444 million, respectively.

In August 2021, a plaintiff filed a putative class action suit in the United States District Court for the Eastern District of Pennsylvania against Takeda and several generic manufacturers, including Watson and Teva, alleging violations of the antitrust laws in connection with their settlement of patent litigation involving colchicine tablets (generic Colcrys®), entered into in January 2016. Plaintiff claims that the settlement was part of a horizontal conspiracy among Takeda and the generic manufacturers to unlawfully restrict output of colchicine by delaying generic entry. Defendants intend to move to dismiss the complaint for failure to state a claim. Annual sales of Colcrys® in the United States were approximately \$187 million at the time of the settlement.

Government Investigations and Litigation Relating to Pricing and Marketing

Teva is involved in government investigations and litigation arising from the marketing and promotion of its pharmaceutical products in the United States.

In 2015 and 2016, Actavis and Teva USA each respectively received subpoenas from the U.S. Department of Justice ("DOJ") Antitrust Division seeking documents and other information relating to the marketing and pricing of certain Teva USA generic products and communications with competitors about such products. On August 25, 2020, a federal grand jury in the Eastern District of Pennsylvania returned a three count indictment charging Teva USA with criminal felony Sherman Act violations. See No. 20-cr-200 (E.D. Pa.). The indictment alleges Teva USA participated in a conspiracy with certain other generic drug manufacturers to maintain and fix prices, allocate customers, and other alleged antitrust offenses concerning the sale of generic drugs. The indictment identified the following generic drugs: Pravastatin, Carbamazepine, Clotrimazole, Etodolac (IR and ER), Fluocinonide (Cream E-Cream, Gel, and Ointment), Warfarin, Nadolol, Temozolomide, and Tobramycin. On September 8, 2020, Teva USA pled not guilty to all counts. A tentative trial date is yet to be scheduled. While the Company is unable to estimate a range of loss at this time, a conviction on these criminal charges could have a material adverse impact on the Company's business, including monetary penalties and debarment from federally funded health care programs.

In May 2018, Teva received a civil investigative demand from the DOJ Civil Division, pursuant to the federal False Claims Act, seeking documents and information produced since January 1, 2009 relevant to the Civil Division's investigation concerning allegations that generic pharmaceutical manufacturers, including Teva, engaged in market allocation and price-fixing agreements, paid illegal remuneration, and caused false claims to be submitted in violation of the False Claims Act. An adverse resolution of this matter may include fines, penalties, financial forfeiture and compliance conditions.

In 2015 and 2016, Actavis and Teva USA each respectively received a subpoena from the Connecticut Attorney General seeking documents and other information relating to potential state antitrust law violations. Subsequently, on December 15, 2016, a civil action was brought by the attorneys general of twenty states against Teva USA and several other companies asserting claims under federal antitrust law alleging price fixing of generic products in the United States. That complaint was later amended to add new states as named plaintiffs, as well as new allegations and new state law claims, and on June 18, 2018, the attorneys general of 49 states plus Puerto Rico and the District of Columbia filed a consolidated amended complaint against Actavis and Teva, as well as other companies and individuals. On May 10, 2019, most (though not all) of these attorneys general filed another antitrust complaint against Actavis, Teva and other companies and individuals, alleging price-fixing and market allocation with respect to additional generic products. On November 1, 2019, the state attorneys general filed an amended complaint, bringing the total number of plaintiff states and territories to 54. The amended complaint alleges that Teva was at the center of a conspiracy in the generic pharmaceutical industry, and asserts that Teva and others fixed prices, rigged bids, and allocated customers and market share with respect to certain additional products. On June 10, 2020, most, but not all, of the same states, with the addition of the U.S. Virgin Islands, filed a third complaint in the District of Connecticut naming, among other defendants, Actavis, but not Teva USA, in a similar complaint relating to dermatological generics products. On September 9, 2021, the states' attorneys general amended their third complaint to, among other things, add California as a plaintiff. In the various complaints described above, the states seek a finding that the defendants' actions violated federal antitrust law and state antitrust and consumer protection laws, as well as injunctive relief, disgorgement, damages on behalf of various state and governmental entities and consumers, civil penalties and costs. All such complaints have been transferred to the generic drug multidistrict litigation in the Eastern District of Pennsylvania ("Pennsylvania MDL"). On July 13, 2020, the court overseeing the Pennsylvania MDL chose the attorneys' general November 1, 2019 amended complaint, referenced above, along with certain complaints filed by private plaintiffs, to proceed first in the litigation as bellwether complaints. Teva moved the court to reconsider that ruling. On February 9, 2021, Teva's motion to reconsider that ruling was granted, and on May 7, 2021, the Court chose the attorneys' general third complaint filed on June 10, 2020 and subsequently amended to serve as a bellwether complaint in the Pennsylvania MDL, along with certain complaints filed by private plaintiffs. In June 2021, Teva settled with the State of Mississippi for \$925,000, and the State dismissed its claims against Actavis and Teva USA, as well as certain former employees of Actavis and Teva USA, pursuant to that settlement.

Beginning on March 2, 2016, and continuing through December 2020, numerous complaints have been filed in the United States on behalf of putative classes of direct and indirect purchasers of several generic drug products, as well as several individual direct and indirect purchaser opt-out plaintiffs. These complaints, which allege that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic products have been brought against various manufacturer defendants, including Teva USA and Actavis. The plaintiffs generally seek injunctive relief and damages under federal antitrust law, and damages under various state laws. On October 16, 2018, the court denied certain of the defendants' motions to dismiss as to certain federal claims, pending as of that date, and on February 15, 2019, the court

granted in part and denied in part defendants' motions to dismiss as to certain state law claims. On July 18, 2019, and again on May 6, 2020, certain individual plaintiffs commenced a civil action in the Pennsylvania Court of Common Pleas of Philadelphia County against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, but no complaint has been filed in either action and, both cases have been placed in deferred status. Certain counties in New York and Texas have also commenced civil actions against many of the defendants in the Pennsylvania MDL, including Teva and Actavis, and the complaints have been, or are in the process of being transferred to the Pennsylvania MDL. There is also one similar complaint brought in Canada, which alleges that the defendants engaged in conspiracies to fix prices and/or allocate market share of generic drug products to the detriment of a class of private payors. The action is in its early stages.

In March 2017, Teva received a subpoena from the U.S. Attorney's office in Boston, Massachusetts requesting documents related to Teva's donations to patient assistance programs. Subsequently, in August 2020, the U.S. Attorney's office in Boston, Massachusetts brought a civil action in the U.S. District Court for the District of Massachusetts alleging violations of the federal Anti-Kickback Statute, and asserting causes of action under the federal False Claims Act and state law. It is alleged that Teva caused the submission of false claims to Medicare through Teva's donations to bona fide independent charities that provide financial assistance to patients. An adverse judgment may involve damages, civil penalties and injunctive remedies. On October 19, 2020, Teva filed a motion to dismiss the complaint on the grounds that it fails to state a claim. On September 10, 2021, the Court granted Teva's motion to dismiss the unjust enrichment claim and denied the remainder of the motion. On October 15, 2021, Teva filed an answer to the complaint. The proceeding is in early stages. Additionally, on January 8, 2021, Humana, Inc. filed an action against Teva in the United States District Court for the Middle District of Florida based on the allegations raised in the August 2020 complaint filed by the U.S. Attorney's Office in Boston. On April 2, 2021, Teva filed a motion to dismiss the claims on the grounds that the claims are time-barred and/or insufficiently pled, and that motion remains pending.

In April 2021, a city and county in Washington sued Teva in the United States District Court for the Western District of Washington for alleged violations of the Racketeer Influenced and Corrupt Organizations Act, Washington's Consumer Protection Act, and unjust enrichment concerning Teva's sale of COPAXONE. Plaintiffs purport to represent a nationwide class of health plans and a subclass of Washington-based health plans that purchased and/or reimbursed health plan members for COPAXONE. Plaintiffs allege that Teva engaged in several fraudulent schemes that resulted in plaintiffs and the putative class members purchasing and/or reimbursing plan members for additional prescriptions of COPAXONE and/or at inflated COPAXONE prices. Plaintiffs seek treble damages for the excess reimbursements and inflated costs, as well as injunctive relief. On September 28, 2021, plaintiffs filed an amended complaint, which Teva plans to move to dismiss.

On June 29, 2021, Mylan Pharmaceuticals sued Teva in District Court for the District of New Jersey for alleged violations of the Lanham Act, unfair competition, monopolization, tortious interference, and trade libel. Plaintiffs claim Teva was involved in an unlawful scheme to delay and hinder generic competition concerning COPAXONE sales. Plaintiffs seek damages for lost profits and expenses, disgorgement, treble damages, attorneys' fees and costs, and injunctive relief. The proceeding is in preliminary stages.

Opioids Litigation

Since May 2014, more than 3,500 complaints have been filed with respect to opioid sales and distribution against various Teva affiliates, along with several other pharmaceutical companies, by a number of cities, counties, states, other governmental agencies, tribes and private plaintiffs (including various putative class actions of individuals) in both state and federal courts. Most of the federal cases have been consolidated into a multidistrict litigation in the Northern District of Ohio ("MDL Opioid Proceeding") and many of the cases filed in state court have been removed to federal court and consolidated into the MDL Opioid Proceeding. Two cases that were included in the MDL Opioid Proceeding were transferred back to federal district court for additional discovery, pre-trial proceedings and trial. Those cases are: City of Chicago v. Purdue Pharma L.P. et al., No. 14-cv-04361 (N.D. Ill.) and City and County of San Francisco v. Purdue Pharma L.P. et al., No. 18-cv-07591-CRB (N.D. Cal.). Other cases remain pending in various states. In some jurisdictions, such as Illinois, New York, Pennsylvania, South Carolina, Texas, Utah and West Virginia, certain state court cases have been transferred to a single court within their respective state court systems for coordinated pretrial proceedings. Complaints asserting claims under similar provisions of different state law, generally contend that the defendants allegedly engaged in improper marketing and distribution of opioids, including ACTIQ® and FENTORA®. The complaints also assert claims related to Teva's generic opioid products. In addition, over 950 personal injury plaintiffs,

including various putative class actions of individuals, have asserted personal injury and wrongful death claims in over 600 complaints, nearly all of which are consolidated in the MDL Opioid Proceeding. Furthermore, approximately 700 non-personal injury complaints and approximately 100 personal injury complaints have named Anda, Inc. (and other distributors and manufacturers) alleging that Anda failed to develop and implement systems sufficient to identify suspicious orders of opioid products and prevent the abuse and diversion of such products to individuals who used them for other than legitimate medical purposes. Plaintiffs seek a variety of remedies, including restitution, civil penalties, disgorgement of profits, treble damages, attorneys' fees and injunctive relief. Certain plaintiffs assert that the measure of damages is the entirety of the costs associated with addressing the abuse of opioids and opioid addiction and certain plaintiffs specify multiple billions of dollars in the aggregate as alleged damages. The individual personal injury plaintiffs further seek non-economic damages. In many of these cases, plaintiffs are seeking joint and several damages among all defendants.

On April 19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced with Teva and other defendants focused on the marketing of branded opioids. On June 29, 2021, a jury trial in New York (In re Opioid Litigation, Index No. 400000/2017)) commenced, with Teva and other defendants, focused on the marketing and distribution of opioids. Absent resolutions, additional trials are expected to proceed in several states in 2022.

In May 2019, Teva settled the Oklahoma litigation brought by the Oklahoma Attorney General (State of Oklahoma, ex. rel. Mike Hunter, Attorney General of Oklahoma vs. Purdue Pharma L.P., et. al.) for \$85 million. The settlement did not include any admission of violation of law for any of the claims or allegations made. As the Company demonstrated a willingness to settle part of the litigation, for accounting purposes, management considered a portion of opioid-related cases as probable and, as such, recorded an estimated provision in the second quarter of 2019. Given the relatively early stage of the cases, management viewed no amount within the range to be the most likely outcome. Therefore, management recorded a provision for the reasonably estimable minimum amount in the assessed range for such opioid-related cases in accordance with Accounting Standards Codification 450 "Accounting for Contingencies."

Additionally, on October 21, 2019, Teva reached a settlement with the two plaintiffs in the MDL Opioid Proceeding that was scheduled for trial for the Track One case, Cuyahoga and Summit Counties of Ohio. Under the terms of the settlement, Teva agreed to provide the two counties with opioid treatment medication, buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone®, with a value of \$25 million at wholesale acquisition cost and distributed over three years to help in the care and treatment of people suffering from addiction, and a cash payment in the amount of \$20 million, which has been paid.

Also on October 21, 2019, Teva and certain other defendants reached an agreement in principle with a group of Attorneys General from North Carolina, Pennsylvania, Tennessee and Texas for a nationwide settlement. This nationwide settlement was designed to provide a mechanism by which the Company attempts to seek resolution of remaining potential and pending opioid claims by both the U.S. states and political subdivisions (i.e., counties, tribes and other plaintiffs) thereof. Under this nationwide settlement, Teva would provide buprenorphine naloxone (sublingual tablets) with an estimated value of up to approximately \$23 billion at wholesale acquisition cost over a ten year period. In addition, Teva would also provide cash payments of up to \$250 million over a ten year period.

During the passage of time since then, the Company has continued to negotiate the terms and conditions of a nationwide settlement. On July 21, 2021, it was announced that four other defendants (not including Teva) have reached a nationwide settlement, subject to certain conditions, which includes payment of up to approximately \$26 billion spread over up to 18 years. The achievement of this settlement may similarly present an opportunity for Teva to arrive at a settlement, although there do remain many complex financial and legal issues still outstanding, including indemnification claims by Allergan against the Company, arising from the acquisition of the Actavis Generics business. The Company cannot predict if a settlement will be finalized.

On September 28, 2021, Teva reached an agreement with the Attorney General of Louisiana that settles the state's opioid-related claims. The agreement is contingent on confirmation from the state by November 2, 2021 that all political subdivisions of Louisiana will release Teva as part of the settlement. Under the terms of the settlement, Teva will pay Louisiana \$15 million over an 18-year period and will provide an additional donation of buprenorphine naloxone (sublingual tablets) valued at \$3 million (wholesale acquisition cost).

The Company considered a range of potential settlement outcomes. The current provision remains a reasonable estimate of the ultimate costs if a settlement is finalized based on the Company's most recent offer to settle. However, if not finalized for the entirety of the cases, a reasonable upper end of a range of loss cannot be determined. An adverse resolution of any of these lawsuits or investigations may involve large monetary penalties, damages, and/or other forms of monetary and non-monetary relief and could have a material and adverse effect on Teva's reputation, business, results of operations and cash flows.

Separately, on April 27, 2018, Teva received subpoena requests from the United States Attorney's office in the Western District of Virginia and the Civil Division seeking documents relating to the manufacture, marketing and sale of branded opioids. In August 2019, Teva received a grand jury subpoena from the United States Attorney's Office for the Eastern District of New York for documents related to the Company's anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers' and distributors' monitoring programs and reporting under the Controlled Substances Act. In September 2019, Teva received subpoenas from the New York State Department of Financial Services (NYDFS) as part of an industry-wide inquiry into the effect of opioid prescriptions on New York health insurance premiums. This was followed by a Statement of Charges and Notice of Hearing filed by the NYDFS, although no hearing date is currently set. Currently, Teva cannot predict how a nationwide settlement (if finalized) will affect these investigations and administrative actions. In addition, a number of state attorneys general, including a coordinated multistate effort, have initiated investigations into sales and marketing practices of Teva and its affiliates with respect to opioids. Other states are conducting their own investigations outside of the multistate group. Teva is cooperating with these ongoing investigations and cannot predict their outcome at this time.

In addition, several jurisdictions and consumers in Canada have initiated litigation regarding opioids alleging similar claims as those in the United States. The cases in Canada may be consolidated and are in their early stages.

Shareholder Litigation

On November 6, 2016 and December 27, 2016, two putative securities class actions were filed in the U.S. District Court for the Central District of California against Teva and certain of its current and former officers and directors. Those lawsuits were consolidated and transferred to the U.S. District Court for the District of Connecticut (the "Ontario Teachers Securities Litigation"). On December 13, 2019, the lead plaintiff in that action filed an amended complaint, purportedly on behalf of purchasers of Teva's securities between February 6, 2014 and May 10, 2019. The amended complaint asserts that Teva and certain of its current and former officers and directors violated federal securities and common laws in connection with Teva's alleged failure to disclose pricing strategies for various drugs in its generic drug portfolio and by making allegedly false or misleading statements in certain offering materials. The amended complaint seeks unspecified damages, legal fees, interest, and costs. In July 2017, August 2017, and June 2019, other putative securities class actions were filed in other federal courts based on similar allegations, and those cases have been transferred to the U.S. District Court for the District of Connecticut. Between August 2017 and September 2021, twenty-two complaints were filed against Teva and certain of its current and former officers and directors seeking unspecified compensatory damages, legal fees, costs and expenses. The similar claims in these complaints have been brought on behalf of plaintiffs, in various forums across the country, who have indicated that they intend to "opt-out" of the Ontario Teachers Securities Litigation. On March 10, 2020, the Court consolidated the Ontario Teachers Securities Litigation with all of the abovereferenced putative class actions for all purposes and the "opt-out" cases for pretrial purposes. Pursuant to that consolidation order, plaintiffs in several of the "opt-out" cases filed amended complaints on May 28, 2020. On January 22, 2021, the Court dismissed the "opt-out" plaintiffs' claims arising from statements made prior to the five year statute of repose, but denied Teva's motion to dismiss their claims under Israeli laws. Those "opt-out" plaintiffs moved for reconsideration, which was denied on March 30, 2021. On May 24, 2021, Teva moved to dismiss a majority of the "opt-out" complaints on various other grounds. The Ontario Teachers Securities Litigation plaintiffs' Motion for Class Certification and Appointment of Class Representatives and Class Counsel was granted on March 9, 2021, to which Teva's appeal was denied. Summary judgment and Daubert motions are currently scheduled to be filed in the Ontario Teachers Securities Litigation in November 2021. The Company is in mediation related to this matter and has recorded a liability in the third quarter of 2021 based upon an offer to settle the class litigation. Accordingly, an insurance receivable in the same amount was recorded. A settlement is subject to alignment with the insurance carriers. There was no net impact to litigation expenses. Motions to approve securities class actions were also filed in the Tel Aviv District Court in Israel with similar allegations to those made in the Ontario Teachers Securities Litigation.

On September 23, 2020, a putative securities class action was filed in the U.S. District Court for the Eastern District of Pennsylvania against Teva and certain of its former officers alleging, among other things, violations of Section 10(b) of the Securities and Exchange Act of 1934, as amended and SEC Rule 10b-5. The complaint, purportedly filed on behalf of persons who purchased or otherwise acquired Teva securities between October 29, 2015 and August 18, 2020, alleges that Teva and certain of its former officers violated federal securities laws by allegedly making false and misleading statements regarding the commercial performance of COPAXONE, namely, by failing to disclose that Teva had caused the submission of false claims to Medicare through Teva's donations to bona fide independent charities that provide financial assistance to patients, which allegedly impacted COPAXONE's commercial success and the sustainability of its revenues and resulted in the above referenced August 2020 False Claims Act complaint filed by the DOJ. On March 26, 2021, the Court appointed lead plaintiff and lead counsel. On May 25, 2021, lead plaintiff filed an amended class action complaint, which named four additional former and current officers as defendants. On August 10, 2021, lead plaintiff moved to strike certain allegations from its amended complaint and to file a corrected amended complaint, which the court granted that same day. The corrected amended complaint seeks unspecified damages and legal fees. On August 23, 2021, Teva moved to dismiss the corrected amended complaint, and that motion remains pending. A motion to approve a securities class action was also filed in the Central District Court in Israel, which has been stayed pending the U.S. litigation, with similar allegations to those made in the above complaint filed in the U.S. District Court for the Eastern District of Pennsylvania.

Motions to approve derivative actions against certain past and present directors and officers have been filed in Israeli Courts alleging negligence and recklessness with respect to the acquisition of the Rimsa business, the acquisition of Actavis Generics and the patent settlement relating to Lidoderm®. Motions for document disclosure prior to initiating derivative actions were filed with respect to several U.S. and EU settlement agreements, opioids, the U.S. price-fixing investigations and allegations related to the DOJ's complaint regarding Copaxone patient assistance program in the U.S. In June 2021, the Tel Aviv District Court approved the settlement reached with respect to the derivative proceeding with regard to the acquisition of Actavis Generics and two related actions, including the derivative proceedings related to allegations in connection with the Lidoderm® patent settlement agreement.

Environmental Matters

Teva or its subsidiaries are party to a number of environmental proceedings, or have received claims, including under the federal Superfund law or other federal, provincial or state and local laws, imposing liability for alleged noncompliance, or for the investigation and remediation of releases of hazardous substances and for natural resource damages. Many of these proceedings and claims seek to require the generators of hazardous wastes disposed of at a third party-owned site, or the party responsible for a release of hazardous substances that impacted a site, to investigate and clean the site or to pay or reimburse others for such activities, including for oversight by governmental authorities and any related damages to natural resources. Teva or its subsidiaries have received claims, or been made a party to these proceedings, along with others, as an alleged generator of wastes that were disposed of or treated at third-party waste disposal sites, or as a result of an alleged release from one of Teva's facilities or former facilities.

Although liability among the responsible parties, under certain circumstances, may be joint and several, these proceedings are frequently resolved so that the allocation of clean-up and other costs among the parties reflects the relative contributions of the parties to the site conditions and takes into account other pertinent factors. Teva's potential liability varies greatly at each of the sites; for some sites the costs of the investigation, clean-up and natural resource damages have not yet been determined, and for others Teva's allocable share of liability has not been determined. At other sites, Teva has taken an active role in identifying those costs, to the extent they are identifiable and estimable, which do not include reductions for potential recoveries of clean-up costs from insurers, indemnitors, former site owners or operators or other potentially responsible parties. In addition, enforcement proceedings relating to alleged violations of federal, state, commonwealth or local requirements at some of Teva's facilities may result in the imposition of significant penalties (in amounts not expected to materially adversely affect Teva's results of operations) and the recovery of certain costs and natural resource damages, and may require that corrective actions and enhanced compliance measures be implemented.

Item 103 of Regulation S-K promulgated by the SEC requires disclosure of certain environmental matters when a governmental authority is a party to the proceedings and such proceedings involve potential monetary sanctions, unless the Company reasonably believes that the matter will result in no monetary sanctions, or in monetary sanctions, exclusive of interest and costs, of less than \$300,000. The following matter is disclosed in accordance with that requirement. On July 8, 2021, the National Green Tribunal Principal Bench, New Delhi, issued an order against Teva's subsidiary in India, Teva API India Private Limited, finding non-compliance with environmental laws and assessed a penalty of \$1.4 million.

The Company disputed certain of the findings and the amount of the penalty and filed an appeal before the Supreme Court of India. On August 5, 2021, the Supreme Court of India admitted the appeal for hearing and granted an interim unconditional stay on the National Green Tribunal's order. The Company does not believe that the eventual outcome of such matter will have a material effect on its business.

Other Matters

On February 1, 2018, former shareholders of Ception Therapeutics, Inc., a company that was acquired by and merged into Cephalon in 2010, prior to Cephalon's acquisition by Teva, filed breach of contract and other related claims against the Company, Teva USA and Cephalon in the Delaware Court of Chancery. Among other things, the plaintiffs allege that Cephalon breached the terms of the 2010 Ception-Cephalon merger agreement by failing to exercise commercially reasonable efforts to develop and commercialize CINQAIR® (reslizumab) for the treatment of eosinophilic esophagitis ("EE"). The plaintiffs claim damages of at least \$200 million, an amount they allege is equivalent to the milestones payable to the former shareholders of Ception in the event Cephalon were to obtain regulatory approval for EE in the United States (\$150 million) and Europe (\$50 million). Defendants moved to dismiss the complaint and on December 28, 2018, the court granted the motion in part and dismissed all of plaintiffs' claims, except for their claim against Cephalon for breach of contract. Trial in this matter is currently scheduled for June 2022.

NOTE 11 – Income taxes:

In the third quarter of 2021, Teva recognized a tax expense of \$76 million, on pre-tax income of \$382 million. In the third quarter of 2020, Teva recognized a tax expense of \$16 million, on pre-tax loss of \$4,459 million. Teva's tax rate for the third quarter of 2021 was mainly affected by amortization and interest expense disallowance.

In the first nine months of 2021, Teva recognized a tax expense of \$235 million, on pre-tax income of \$833 million. In the first nine months of 2020, Teva recognized a tax benefit of \$147 million, on pre-tax loss of \$4,543 million. Teva's tax rate for the first nine months of 2021 was mainly affected by amortization, impairments, legal settlements and interest expense disallowance.

The statutory Israeli corporate tax rate is 23% in 2021. Teva's tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits in Israel and other countries, as well as infrequent or non-recurring items.

Teva filed a claim seeking the refund of withholding taxes paid to the Indian tax authorities in 2012. Trial in this case is scheduled to begin on October 29, 2021. A final and binding decision against Teva in this case may lead to an asset write off of \$141 million.

The Israeli tax authorities issued tax assessment decrees for 2008-2012 and 2013-2016, challenging the Company's positions on several issues. Teva has protested the 2008-2012 and 2013-2016 decrees before the Central District Court in Israel. The Company believes it has adequately provided for these items, however, adverse results could be material.

NOTE 12 – Other assets impairments, restructuring and other items:

	Three months ended September 30,	Nine months ended September 30,
	2021 2020		2021	2020
		(U.S. \$ in millions)		(U.S. \$ in millions)
Impairments of long-lived tangible assets (1)	\$ 26	\$ 56	\$ 106	\$ 408
Contingent consideration	9	(179)	(7)	(96)
Restructuring	28	9	96	82
Other	(1)	15	32	10
Total	\$ 62	\$ (98)	\$ 227	\$ 404

(1) Including impairments related to exit and disposal activities

Impairments

Impairments of tangible assets for the three months ended September 30, 2021 and 2020 were \$26 million and \$56 million, respectively. The impairment for the three months ended September 30, 2021 was mainly related to certain assets in North America. The impairment for the three months ended September 30, 2020 was mainly related to the intention to sell certain assets in Teva's International Markets and Europe segments.

Impairments of tangible assets for the nine months ended September 30, 2021 and 2020 were \$106 million and \$408 million, respectively. The impairment for the nine months ended September 30, 2021 was mainly related to certain assets in the Europe and North America segments. The impairment for the nine months ended September 30, 2020 was mainly related to the intention to sell certain assets from Teva's business venture in Japan and plant rationalization. See note 2.

Teva may record additional impairments in the future, to the extent it changes its plans on any given asset and/or the assumptions underlying such plans, as a result of its network consolidation activities.

Contingent consideration

In the three months ended September 30, 2021, Teva recorded an expense of \$9 million for contingent consideration, compared to an income of \$179 million in the three months ended September 30, 2020. The expense in the third quarter of 2021 was mainly related to a change in the estimated future royalty payments to Eagle Pharmaceuticals, Inc. ("Eagle") in connection with expected future bendamustine sales. The income in the third quarter of 2020 was mainly related to a change in the future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid®), which was part of the Actavis Generics acquisition.

In the nine months ended September 30, 2021, Teva recorded income of \$7 million for contingent consideration, compared to income of \$96 million in the nine months ended September 30, 2020. The income in the first nine months of 2021 was mainly related to a change in the estimated future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid®), which was part of the Actavis Generics acquisition, partially offset by the change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales. The income in the first nine months of 2020 was mainly related to a change in the future royalty payments to Allergan in connection with lenalidomide (generic equivalent of Revlimid®), which was part of the Actavis Generics acquisition, partially offset by the change in the estimated future royalty payments to Eagle in connection with expected future bendamustine sales.

Restructuring

In the three months ended September 30, 2021, Teva recorded \$28 million of restructuring expenses, compared to \$9 million of restructuring expenses in the three months ended September 30, 2020. The expenses for the three months ended September 30, 2021 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017.

In the nine months ended September 30, 2021, Teva recorded \$96 million of restructuring expenses, compared to \$82 million in the nine months ended September 30, 2020. The expenses for the nine months ended September 30, 2021 and September 30, 2020 were primarily related to network consolidation activities and residual expenses of the restructuring plan announced in 2017.

The following tables provide the components of costs associated with Teva's restructuring plan, including other costs associated with Teva's restructuring plan and recorded under different items:

	Three months ended September 30,
	2021		2020
	(U.S. \$ in millions)
Restructuring
Employee termination	\$ 24	\$	3
Other	4		7
Total	\$ 28	\$	9

	Nine months ended September 30,
	2021		2020
	(U.S. \$ in millions)
Restructuring
Employee termination	\$ 84	\$	39
Other	12		43
Total	\$ 96	\$	82

The following table provides the components of and changes in the Company's restructuring accruals:

	Employee termination costs		Other	Total
		(U.S. \$ in millions )
Balance as of January 1, 2021	\$	(115)	\$ (7)	\$(122)
Provision		(84)	(12)	(96)
Utilization and other*		78	12	90
Balance as of September 30, 2021	\$	(121)	\$ (7)	\$(128)

	Employee termination costs		Other	Total
		(U.S. \$ in millions )
Balance as of January 1, 2020	\$	(208)	\$ (7)	\$(215)
Provision		(39)	(43)	(82)
Utilization and other*		145	43	188
Balance as of September 30, 2020	\$	(102)	\$ (7)	\$(109)

* Includes adjustments for foreign currency translation.

Significant regulatory and other events

In July 2018, the FDA completed an inspection of Teva's manufacturing plant in Davie, Florida in the United States, and issued a Form FDA-483 to the site. In October 2018, the FDA notified Teva that the inspection of the site had been classified as "official action indicated" ("OAI"), and on February 5, 2019, Teva received a warning letter from the FDA that contained four additional enumerated concerns related to production, quality control and investigations at this site. Since the inspection, Teva has been working diligently to address the FDA's concerns in a manner consistent with current good manufacturing practice (CGMP) requirements as quickly and as thoroughly as possible. FDA follow up inspections occurred in January 2020 and in May 2021. In an official "Warning Letter Closeout Letter" dated September 1, 2021, FDA notified Teva that FDA had completed its evaluation of Teva's corrective actions, and it appeared that Teva had adequately addressed the warning letter.

In July 2018, Teva announced the voluntary recall of valsartan and certain combination valsartan medicines in various countries due to the detection of trace amounts of a previously unknown nitrosamine impurity called NDMA found in valsartan API supplied by Zhejiang Huahai Pharmaceuticals Co. Ltd. ("Huahai"). Since July 2018, Teva has been actively engaged with global regulatory authorities in reviewing its sartan and other products to determine whether NDMA and/or other related nitrosamine impurities are present in specific products. Where necessary, Teva has initiated additional voluntary recalls. In December 2019, Teva reached a settlement with Huahai resolving Teva's claims related to certain sartan API supplied by Huahai. Under the settlement agreement, Huahai agreed to compensate Teva for some of its direct losses and provide it with prospective cost reductions for API. The settlement does not release Huahai from liability for any losses Teva may incur as a result of third party personal injury or product liability claims relating to the sartan API at issue. In addition, multiple lawsuits have been filed in connection with this matter, which may lead to additional customer penalties, impairments and litigation costs.

In the second quarter of 2020, Teva's operations in its manufacturing facilities in Goa, India were temporarily suspended due to a water supply issue. During the second half of 2020, Teva completed partial remediation of this issue and restarted limited supply from its Goa facilities. The site experienced some additional delays in the first quarter of 2021 due to labor related issues, but the situation stabilized during the second quarter of 2021. The impact to Teva's financial results for the nine months ended September 30, 2021 was immaterial, however, if the full remediation takes longer than expected there may be further loss of sales, customer penalties or impairments to related assets.

In June 2021, the Company temporarily paused manufacturing at its Irvine, California facility in the United States, and suspended release of product from the facility pending completion of an open manufacturing investigation. In July 2021, the FDA initiated an establishment inspection at the facility. During the period from February 2021 through July 2021, the Company voluntarily initiated recalls of specific lots of multiple products from the facility. On August 18, 2021, the Company issued field alert reports to FDA for products manufactured at the Irvine facility and put Irvine manufactured product in Teva's distribution center on hold. On August 20, 2021, the FDA completed its inspection and issued a Form FDA-483 to the Irvine facility with ten observations. Teva has been working diligently to address the FDA's concerns in a manner consistent with current good manufacturing practice (CGMP) requirements as quickly and as thoroughly as possible. In addition, Teva is in discussions with the FDA Drug Shortage Staff (DSS) and FDA Office of Manufacturing Quality (OMQ) in an effort to allow for the distribution and re-start of manufacturing of certain medically necessary products to minimize the impact on patients. Suspension of manufacturing and distribution for an extended period or if Teva is unable to address additional inspection issues satisfactorily, could subject Teva to additional consequences. Teva has considered these developments and has recorded immaterial costs in its financial statements related to this matter. Teva will continue to assess potential financial implications, including due to loss of revenues, impairments, inventory write offs, customer penalties, idle capacity charges, costs of additional remediation and/or FDA enforcement actions.

NOTE 13 – Earnings (Loss) per share:

Basic earnings and loss per share are computed by dividing net results attributable to Teva's ordinary shareholders by the weighted average number of ordinary shares outstanding (including fully vested restricted share units ("RSUs")) during the period, net of treasury shares.

In computing diluted earnings per share for the three months ended September 30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.

In computing diluted loss per share for the three months ended September 30, 2020, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.

In computing diluted earnings per share for the nine months ended September 30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.

In computing diluted loss per share for the nine months ended September 30, 2020, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.

Basic and diluted earnings per share were \$0.26 for the three months ended September 30, 2021, compared to basic and diluted loss per share of \$3.97 for the three months ended September 30, 2020.

Basic and diluted earnings per share were \$0.52 for the nine months ended September 30, 2021, compared to basic and diluted loss per share of \$3.78 for the nine months ended September 30, 2020.

NOTE 14 – Accumulated other comprehensive income (loss):

The components of, and changes within, accumulated other comprehensive income (loss) attributable to Teva are presented in the table below:

	Net Unrealized Gains (Losses) Foreign currency translation adjustments	Derivative financial instruments	Benefit Plans Actuarial gains (losses) and prior service (costs) credits	Total
		(U.S. \$ in millions)
Balance as of December 31, 2020, net of taxes	\$ (1,919)	\$ (363)	\$ (117)	\$(2,399)
Other comprehensive income (loss) before reclassifications	(270)	—	—	(270)
Amounts reclassified to the statements of income	—	27	2	29
Net other comprehensive income (loss) before tax	(270)	27	2	(241)
Corresponding income tax	26	(6)	—	20
Net other comprehensive income (loss) after tax*	(244)	21	2	(221)
Balance as of September 30, 2021, net of taxes	\$ (2,163)	\$ (342)	\$ (115)	\$(2,620)

* Amounts do not include a \$81 million loss from foreign currency translation adjustments attributable to non-controlling interests.

	Net Unrealized Gains (Losses) Foreign currency translation adjustments	Derivative financial instruments	Benefit Plans Actuarial gains (losses) and prior service (costs) credits	Total
Balance as of December 31, 2019, net of taxes	\$ (1,794)	(U.S. \$ in millions) \$ (420)	\$ (98)	\$(2,312)
Other comprehensive income (loss) before reclassifications	(418)	20	—	(398)
Amounts reclassified to the statements of income	—	26	—	26
Net other comprehensive income (loss) before tax	(418)	46	—	(372)
Corresponding income tax	41	—	—	41
Net other comprehensive income (loss) after tax*	(377)	46	—	(331)
Balance as of September 30, 2020, net of taxes	\$ (2,171)	\$ (374)	\$ (98)	\$(2,643)

* Amounts do not include a \$29 million gain from foreign currency translation adjustments attributable to non-controlling interests.

NOTE 15 – Segments:

Teva operates its business and reports its financial results in three segments:

• (a) North America segment, which includes the United States and Canada.
• (b) Europe segment, which includes the European Union and certain other European countries.
• (c) International Markets segment, which includes all countries other than those in the North America and Europe segments.

In addition to these three segments, Teva has other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Teva's Chief Executive Officer ("CEO"), who is the chief operating decision maker ("CODM"), reviews financial information prepared on a consolidated basis, accompanied by disaggregated information about revenues and contributed profit by the three identified reportable segments, namely North America, Europe and International Markets, to make decisions about resources to be allocated to the segments and assess their performance.

Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items.

Teva manages its assets on a company basis, not by segments, as many of its assets are shared or commingled. Teva's CODM does not regularly review asset information by reportable segment and, therefore, Teva does not report asset information by reportable segment.

Teva's CEO may review its strategy and organizational structure from time to time. Any changes in strategy may lead to a reevaluation of the Company's segments and goodwill allocation to reporting units, as well as fair value attributable to its reporting units. See note 3 and note 6.

a. Segment information:

	Three months ended September 30,
	2021
	North America	Europe	International Markets
		(U.S. \$ in millions)
Revenues	\$ 1,875	\$1,220	\$	530
Gross profit	967	714		296
R&D expenses	146	55		16
S&M expenses	250	204		102
G&A expenses	121	64		29
Other income	(7)	(2)		(2)
Segment profit	\$ 458	\$ 394	\$	152

§ Represents an amount less than \$1 million.

		Three months ended September 30, 2020
		North America	Europe		International Markets
			(U.S. \$ in millions)
Revenues	\$	2,017	\$1,116	\$	529
Gross profit		1,056	637		275
R&D expenses		155	60		17
S&M expenses		250	200		101
G&A expenses		97	66		33
Other income		(5)	(1)		(1)
Segment profit	\$	560	\$ 312	\$	125

	Nine months ended September 30,
	2021
	North America	Europe	International Markets
		(U.S. \$ in millions)
Revenues	\$ 5,807	\$3,618	\$	1,505
Gross profit	3,081	2,063		826
R&D expenses	467	184		51
S&M expenses	734	628		303
G&A expenses	338	180		79
Other income	(14)	(3)		(5)
Segment profit	\$ 1,556	\$1,074	\$	398

		Nine months ended September 30, 2020
		North America	Europe	International Markets
			(U.S. \$ in millions)
Revenues	\$	6,146	\$3,520	\$	1,582
Gross profit		3,208	2,009		828
R&D expenses		455	180		51
S&M expenses		755	590		312
G&A expenses		325	184		96
Other income		(9)	(3)		(10)
Segment profit	\$	1,682	\$1,058	\$	378

The following table presents a reconciliation of Teva's segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three and nine months ended September 30, 2021 and 2020:

		Three months ended September 30,		Nine months ended September 30,
	2021	2020 (U.S. \$ in millions)	2021	2020 (U.S. \$ in millions)
North America profit	\$ 458	\$ 560	\$1,556	\$ 1,682
Europe profit	394	312	1,074	1,058
International Markets profit	152	125	398	378
Total reportable segments profit	1,004	997	3,028	3,118
Profit of other activities	38	28	125	130
Total segments profit	1,042	1,025	3,153	3,248
Amounts not allocated to segments:
Amortization	199	251	613	758
Other assets impairments, restructuring and other items	62	(98)	227	404
Goodwill impairment	—	4,628	—	4,628
Intangible asset impairments	21	509	295	1,278
Legal settlements and loss contingencies	3	21	113	10
Other unallocated amounts	134	55	266	148
Consolidated operating income (loss)	623	(4,342)	1,638	(3,978)
Financial expenses, net	241	117	805	565
Consolidated income (loss) before income taxes	\$ 382	\$(4,459)	\$ 833	\$(4,543)

b. Segment revenues by major products and activities:

The following tables present revenues by major products and activities for the three and nine months ended September 30, 2021 and 2020:

North America		Three months ended September 30,
	2021	2020
		(U.S. \$ in millions)
Generic products	\$ 859	\$ 928
AJOVY	46	35
AUSTEDO	201	168
BENDEKA®/TREANDA®	95	105
COPAXONE	133	236
ProAir®*	31	50
Anda	363	341
Other	146	155
Total	\$1,875	\$2,017

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

North America		Nine months ended September 30,
	2021	2020
		(U.S. \$ in millions)
Generic products	\$2,864	\$2,804
AJOVY	123	98
AUSTEDO	520	451
BENDEKA/TREANDA	292	313
COPAXONE	448	671
ProAir*	140	175
Anda	968	1,141
Other	451	493
Total	\$5,807	\$6,146

44

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

Europe		Three months ended September 30,
	2021	2020
	(U.S. \$ in millions)
Generic products	\$ 895 \$	824
AJOVY	23	8
COPAXONE	95	101
Respiratory products	85	77
Other	122	106
Total	\$1,220	\$1,116
Europe	Nine months ended September 30,
	2021	2020
	(U.S. \$ in millions)
Generic products	\$2,637	\$2,593
AJOVY	58	17
COPAXONE	296	294
Respiratory products	263	263
Other	364	352
Total	\$3,618	\$3,520
International markets	2021	Three months ended September 30, 2020
	(U.S. \$ in millions)
Generic products	\$ 412 \$	429
AJOVY	39	16
COPAXONE	10	14
Other	69	71
Total	\$ 530 \$	529
International markets	Nine months ended September 30, 2021 (U.S. \$ in millions)	2020
Generic products	\$1,211	\$1,304
AJOVY	46	17
COPAXONE	29	38
Other	219	224

45

Total \$ 1,505 \$ 1,582

NOTE 16 – Fair value measurement:

Financial items carried at fair value on a recurring basis as of September 30, 2021 and December 31, 2020 are classified in the tables below in one of the three categories of fair value levels:

	September 30, 2021
	Level 1	Level 2	Level 3	Total
		(U.S. \$ in millions)
Cash and cash equivalents:
Money markets	\$ 325	\$ —	\$ —	\$ 325
Cash, deposits and other	1,720	—	—	1,720
Investment in securities:
Equity securities	18	—	—	18
Other, mainly debt securities	5	—	1	6
Derivatives:
Asset derivatives—options and forward contracts	—	45	—	45
Liability derivatives—options and forward contracts	—	(23)	—	(23)
Contingent consideration**	—	—	(187)	(187)
Total	\$2,068	\$ 22	\$ (186)	\$1,904

	December 31, 2020
	Level 1	Level 2	Level 3	Total
		(U.S. \$ in millions)
Cash and cash equivalents:
Money markets	\$ 367	\$ —	\$ —	\$ 367
Cash, deposits and other	1,810	—	—	1,810
Investment in securities:
Equity securities*	25	259	—	284
Other, mainly debt securities	5	—	10	15
Derivatives:
Asset derivatives—options and forward contracts	—	24	—	24
Liability derivatives—options and forward contracts	—	(79)	—	(79)
Contingent consideration**	—	—	(268)	(268)
Total	\$2,207	\$ 204	\$ (258)	\$2,153

* During the first quarter of 2021, Teva's shares in American Well Corporation ("American Well") moved from a Level 2 measurement to a Level 1 measurement within the fair value hierarchy, since they were no longer subject to a sale restriction. As of September 30, 2021, Teva sold all of its holdings in American Well.

** Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.

Teva determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected from the success of unapproved product candidates; the probability of success of product candidates, including risks associated with uncertainty regarding achievement and payment of milestone events; the time and resources needed to complete the development and approval of product candidates; the life of the potential commercialized products and associated risks of obtaining regulatory approvals in the United States and Europe, and the risk adjusted discount rate for fair value measurement. A probability of success factor ranging from 90% to 100% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied ranged from 7.3% to 7.8%. The weighted average discount rate, calculated based on the relative fair value of Teva's contingent consideration liabilities, was 7.5%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities.

The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs:

	Nine months ended September 30, 2021	Nine months ended September 30, 2020
	(U.S. \$ in millions)
Fair value at the beginning of the period	\$ (258)	(448)
Transfer into Level 3- equity securities	—	179
Revaluation of equity securities	—	118
Redemption of debt securities	(9)	—
Revaluation of debt securities	—	(3)
Adjustments to provisions for contingent consideration:
Actavis Generics transaction	21	161
Eagle transaction	(14)	(65)
Settlement of contingent consideration:
Eagle transaction	74	85
Fair value at the end of the period	\$ (186)	\$ 27

Financial instruments not measured at fair value

Financial instruments measured on a basis other than fair value mostly consist of senior notes and convertible senior debentures (see note 7) and are presented in the table below in terms of fair value (level 1 inputs):

	Estimated fair value*
	September 30, 2021			December 31, 2020
	(U.S. \$ in millions)
Senior notes included under senior notes and loans	\$	21,018	\$	22,684
Senior notes and convertible senior debentures included under short-term
debt		2,413		3,207
Total	\$	23,431	\$	25,891

* The fair value was estimated based on quoted market prices.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Business Overview

We are a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their health. Our mission is to be a global leader in generics, specialty medicines and biopharmaceuticals, improving the lives of patients.

We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Our key strengths include our world-leading generic medicines expertise and portfolio, focused specialty medicines portfolio and global infrastructure and scale.

Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901.

Our Business Segments

We operate our business through three segments: North America, Europe and International Markets. Each business segment manages our entire product portfolio in its region, including generics, specialty and OTC products. This structure enables strong alignment and integration between operations, commercial regions, R&D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas.

In addition to these three segments, we have other activities, primarily the sale of API to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis.

The COVID-19 Pandemic

As a leading global pharmaceutical company, Teva provides essential medicines to millions of patients around the world every day. Our priorities remain focused on the health and well-being of our employees and on our responsibility to continue to provide our medicines to the nearly 200 million patients who depend on us every day.

During the third quarter of 2021, we have not experienced material delays in development, production and distribution of medicines or disruptions in our supply chains. The supply chain supporting our key products – specialty, generics and API – remains largely uninterrupted, with adequate product inventory across our network and redundancy plans in place to address potential shortfalls, if any. All our facilities that research, manufacture, order, pack, distribute and provide critical customer and patient services are currently functioning to meet demand for essential medicines for patients throughout the world.

We did not have and do not expect to have a material impact on our ongoing clinical research programs and product launches as a result of the COVID-19 pandemic; however, during the third quarter of 2021, we have experienced minimal delays in clinical trials due to cessation or slow-downs of recruitment for patient studies and suspended regulatory inspections, raw material supply issues, delays in regulatory approvals of new products due to reduced capacity or re-prioritization of regulatory agencies and delays in pre-commercial launch activities. We may experience further delays if the pandemic continues for an extended period of time. All of our new product launches have been risk-assessed based on upcoming manufacturing and regulatory inspections.

The long-term effects of the pandemic cannot be predicted at this time and would depend on the duration and severity of the pandemic and the restrictive measures put in place to control its impact. In the first quarter of 2020, we experienced increasing demand for certain medicines, as would be expected during a global crisis of this nature. We saw a compensating effect with lower demand for certain medicines during the second quarter of 2020 and continuing slightly lower demand due to less physician and hospital activity in certain regions and for certain medicines in the second half of 2020. During the first nine months of 2021, the COVID-19 pandemic has continued to have an impact on markets and on customer stocking and purchasing patterns. Although no one can predict future demand for pharmaceutical products, market dynamics or the scope or duration of the financial and other challenges arising from the pandemic, it is possible that we will continue to see variable demand in future periods. While COVID-19 continues to impact sales in certain markets and for certain products, we do not currently anticipate a material negative impact on our 2021 financial results due to the ongoing global pandemic.

Highlights

Significant highlights in the third quarter of 2021 included:

• Revenues in the third quarter of 2021 were \$3,887 million, a decrease of 2%, or 3% in local currency terms, compared to the third quarter of 2020. This decrease was mainly due to lower revenues in our North America segment, mainly due to COPAXONE and generic products, partially offset by higher revenues from generic and OTC products in our Europe segment, AJOVY and AUSTEDO. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and on customer stocking and purchasing patterns.
• Our North America segment generated revenues of \$1,875 million and profit of \$458 million in the third quarter of 2021. Revenues decreased by 7% compared to the third quarter of 2020, mainly due to a decrease in revenues from COPAXONE and generic products. Our North America segment has experienced some reductions in volume due to less physician and hospital activity during the COVID-19 pandemic, but has also experienced increase in demand for certain products related to the treatment of COVID-19 and its symptoms. In addition, the ability to promote certain specialty products has been impacted by less physician visits by patients and less physician interactions by our sales personnel. Profit decreased by 18% compared to the third quarter of 2020, mainly due to lower gross profit.
• Our Europe segment generated revenues of \$1,220 million and profit of \$394 million in the third quarter of 2021. Revenues increased by 9%, or 6% in local currency terms, compared to the third quarter of 2020. This increase was mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns. Profit increased by 26%, mainly due to higher revenues.
• Our International Markets segment generated revenues of \$530 million and profit of \$152 million in the third quarter of 2021. Revenues were flat in U.S. dollar terms, but increased by 1% in local currency terms, compared to the third quarter of 2020, mainly due to higher revenues in most markets and a milestone payment of \$35 million from Otsuka related to the launch of AJOVY in Japan, partially offset by lower revenues in Japan resulting from the divestment of the majority of the generic and operational assets of our business venture in Japan, as well as regulatory price reductions and generic competition to off-patented products. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and on customer stocking and purchasing patterns. Profit increased by 22%, mainly due to higher gross profit.
• Impairments of identifiable intangible assets were \$21 million in the third quarter of 2021, compared to \$509 million in the third quarter of 2020. See note 5 to our consolidated financial statements.
• No goodwill impairment charges were recorded in the third quarter of 2021, compared to a goodwill impairment charge of \$4,628 million in the third quarter of 2020.
• We recorded other asset impairments, restructuring and other items expenses of \$62 million in the third quarter of 2021, compared to income of \$98 million in the third quarter of 2020. See note 12 to our consolidated financial statements.
• Legal settlements and loss contingencies expenses were \$3 million in the third quarter of 2021, compared to \$21 million in the third quarter of 2020. See note 9 to our consolidated financial statements.
• Operating income was \$623 million in the third quarter of 2021, compared to a loss of \$4,342 million in the third quarter of 2020. The operating loss in the third quarter of 2020 was mainly due to a goodwill impairment charge and higher intangible asset impairment charges.
• Financial expenses were \$241 million in the third quarter of 2021, compared to \$117 million in the third quarter of 2020. Financial expenses in the third quarter of 2021 were mainly comprised of interest expenses of \$232 million. Financial expenses in the third quarter of 2020 were mainly comprised of interest expenses of \$241 million, partially offset by gains on revaluations of marketable securities of \$124 million.
• In the third quarter of 2021, we recognized a tax expense of \$76 million, on pre-tax income of \$382 million. In the third quarter of 2020, we recognized a tax expense of \$16 million, on pre-tax loss of \$4,459 million. Our tax rate for the third quarter of 2021 was mainly affected by amortization and interest expense disallowance.

• Exchange rate movements during the third quarter of 2021, including hedging effects, positively impacted revenues by \$42 million and operating income by \$22 million, compared to the third quarter of 2020.

• As of September 30, 2021, our debt was \$23,746 million, compared to \$25,132 million as of June 30, 2021. This decrease was mainly due to repayment of our \$1,475 million 2.2% senior notes at maturity and exchange rate fluctuations, partially offset by \$300 million borrowed under our revolving credit facility.

• Cash flow generated from operating activities during the third quarter of 2021 was \$529 million, compared to \$307 million in the third quarter of 2020. The increase in the third quarter of 2021 was mainly due to favorable collection of payments from customers in North America.
• During the third quarter of 2021, we generated free cash flow of \$795 million, which we define as comprising \$529 million in cash flow generated from operating activities, \$397 million in beneficial interest collected in exchange for securitized accounts receivables and \$15 million in proceeds from divestitures of businesses and other assets, partially offset by \$146 million in cash used for capital investment. During the third quarter of 2020, we generated free cash flow of \$506 million, comprising \$307 million in cash flow generated from operating activities, \$333 million in beneficial interest collected in exchange for securitized accounts receivables and \$9 million in proceeds from sale of property, plant and equipment and intangible assets, partially offset by \$143 million in cash used for capital investment. The increase in the third quarter of 2021 resulted mainly from higher cash flow from operating activities.

Results of Operations

Comparison of Three Months Ended September 30, 2021 to Three Months Ended September 30, 2020

Segment Information

North America Segment

The following table presents revenues, expenses and profit for our North America segment for the three months ended September 30, 2021 and 2020:

		Three months ended September 30,
		2021	2020
		(U.S. \$ in millions / % of Segment Revenues)
Revenues	\$1,875	100%	\$2,017	100%
Gross profit	967	51.6%	1,056	52.4%
R&D expenses	146	7.8%	155	7.7%
S&M expenses	250	13.3%	250	12.4%
G&A expenses	121	6.4%	97	4.8%
Other income	(7)	§	(5)	§
Segment profit*	\$ 458	24.4%	\$ 560	27.7%

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than 0.5%.

North America Revenues

Our North America segment includes the United States and Canada. Revenues from our North America segment in the third quarter of 2021 were \$1,875 million, a decrease of \$142 million, or 7%, compared to the third quarter of 2020, mainly due to a decrease in revenues from COPAXONE and generic products. Our North America segment has

experienced some reductions in volume due to less physician and hospital activity during the COVID-19 pandemic, but has also experienced increase in demand for certain products related to the treatment of COVID-19 and its symptoms. In addition, the ability to promote certain specialty products has been impacted by less physician visits by patients and less physician interactions by our sales personnel.

Revenues by Major Products and Activities

The following table presents revenues for our North America segment by major products and activities for the three months ended September 30, 2021 and 2020:

	Three months ended September 30,			Percentage Change 2020-2021
	2021 2020
Generic products	\$ 859	(U.S. \$ in millions) \$	928	(7%)
AJOVY	46		35	31%
AUSTEDO	201		168	19%
BENDEKA/TREANDA	95		105	(9%)
COPAXONE	133		236	(44%)
ProAir*	31		50	(37%)
Anda	363		341	7%
Other	146		155	(5%)
Total	\$ 1,875	\$ 2,017		(7%)

* Does not include revenues from our ProAir authorized generic, which are included under generic products.

Generic products revenues in our North America segment (including biosimilars) in the third quarter of 2021 were \$859 million, a decrease of 7% compared to the third quarter of 2020, mainly due to increased competition and lower volumes.

Among the most significant generic products we sold in North America in the third quarter of 2021 were epinephrine injectable solution (the generic equivalent of EpiPen® and EpiPen Jr.®), Truxima (the biosimilar to Rituxan®), albuterol sulfate inhalation aerosol (our ProAir authorized generic) and lidocaine transdermal patch (the generic equivalent of Lidoderm Patch®).

In the third quarter of 2021, our total prescriptions were approximately 305 million (based on trailing twelve months), representing 8.2% of total U.S. generic prescriptions according to IQVIA data.

AJOVY revenues in our North America segment in the third quarter of 2021 increased by 31% to \$46 million, compared to the third quarter of 2020, mainly due to growth in volume. In the third quarter of 2021, AJOVY's exit market share in the United Stated in terms of total number of prescriptions was 21.4% compared to 18.5% in the third quarter of 2020.

AJOVY is indicated for the preventive treatment of migraine in adults. AJOVY was launched in the U.S. in 2018, and was approved in Canada in April 2020. Our auto-injector device for AJOVY became commercially available in the U.S. in April 2020 and in Canada in April 2021. AJOVY is the only anti-CGRP product indicated for quarterly treatment and in January 2021 we launched a new product offering, providing a quarterly dose.

AJOVY is protected by patents expiring in 2026 in Europe and in 2027 in the United States. Applications for patent term extensions have been submitted in various markets around the world, and certain extensions in Europe and other countries have already been granted until 2031. Additional patents relating to the use of AJOVY in the treatment of migraine have also been issued in the United States and will expire between 2035 and 2039. Such patents are also pending in other countries. AJOVY will also be protected by regulatory exclusivity for 12 years from marketing approval in the United States and 10 years from marketing approval in Europe. We have filed a lawsuit in the U.S. District Court for the

District of Massachusetts alleging that Eli Lilly & Co.'s ("Lilly") marketing and sale of its galcanezumab product for the treatment of migraine infringes nine Teva patents. Lilly then submitted IPR (inter partes review) petitions to the Patent Trial and Appeal Board, challenging the validity of the nine patents asserted against it in the litigation. The litigation in the district court was stayed pending resolution of the IPR petitions. On February 18, 2020, the Patent Trial and Appeal Board issued decisions on the first six IPRs, finding the six composition of matter patents invalid as being obvious and we have appealed these decisions. On March 31, 2020, the Patent Trial and Appeal Board ("PTAB") issued a decision upholding the three method of treatment patents and Lilly appealed the decisions on these three patents. The Court of Appeals for the Federal Circuit heard oral argument for the IPR appeals on June 7, 2021 and on August 16, 2021 affirmed the PTAB's decisions. The litigation is proceeding with the three method of treatment patents and trial in front of a jury will take place in the second quarter of 2022. We also filed another suit against Lilly on June 8, 2021, asserting two patents which issued that same day and relate to the treatment of refractory migraine. The case has been assigned to the same judge in the U.S. District Court for the District of Massachusetts. Lilly responded to the complaint with a motion to dismiss, which we are opposing. In addition, in 2018 we entered into separate agreements with Alder Biopharmaceuticals, Inc. and Lilly, resolving the European Patent Office oppositions that they filed against our AJOVY patents. The settlement agreement with Lilly also resolved Lilly's action to revoke the patent protecting AJOVY in the United Kingdom.

AUSTEDO revenues in our North America segment in the third quarter of 2021 increased by 19%, to \$201 million, compared to \$168 million in the third quarter of 2020, mainly due to growth in volume.

AUSTEDO was launched in the U.S. in 2017. It is indicated for the treatment of chorea associated with Huntington disease and for the treatment of tardive dyskinesia in adults.

AUSTEDO is protected in the United States by six Orange Book patents expiring between 2031 and 2036 and in Europe by two patents expiring in 2029. We received notice letters from two ANDA filers regarding the filing of their ANDAs with paragraph (IV) certifications for certain of the patents listed in the Orange Book for AUSTEDO. On July 1, 2021, we filed a complaint against Aurobindo, asserting all six of the Orange Book patents, and a separate complaint against Lupin, asserting four of the Orange Book patents. The suits were filed in the U.S. District Court for the District of New Jersey. In addition, Apotex has filed a petition for inter partes review by the PTAB of the patent that expires in 2031.

BENDEKA and TREANDA combined revenues in our North America segment in the third quarter of 2021 decreased by 9% to \$95 million, compared to the third quarter of 2020, mainly due to the availability of alternative therapies and continued competition from Belrapzo® (a ready-to-dilute bendamustine hydrochloride product from Eagle).

In July 2018, Eagle prevailed in its suit against the FDA to obtain seven years of orphan drug exclusivity in the United States for BENDEKA. On March 13, 2020, this decision was upheld in the appellate court. As things currently stand, drug applications referencing BENDEKA, TREANDA or any other bendamustine product will not be approved by the FDA until the orphan drug exclusivity expires in December 2022. In April 2019, we signed an amendment to the license agreement with Eagle extending the royalty term applicable to the United States to the full period for which we sell BENDEKA and increased the royalty rate. In consideration, Eagle agreed to assume a portion of BENDEKA-related patent litigation expenses.

There are 16 patents listed in the U.S. Orange Book for BENDEKA with expiry dates in 2026 and 2031. In September 2019, a patent infringement action against four of six ANDA filers for generic versions of BENDEKA was tried in the United States District Court for the District of Delaware. On April 27, 2020, the District Court upheld the validity of all of the asserted patents and found that all four ANDA filers infringe at least one of the patents. Three of the four ANDA filers appealed the district court decision. Teva settled with one of the three ANDA filers prior to oral argument in front of the Federal Circuit, and on August 13, 2021, the Federal Circuit issued a Rule 36 affirmance of the district court decision. A litigation against the fifth ANDA filer was dismissed after the withdrawal of its patent challenge, and the case against a sixth ANDA filer was also settled. Recent suits against two filers of 505(b)(2) NDAs referencing BENDEKA are also in the initial stages of litigation.

Additionally, in July 2018, Teva and Eagle filed suit against Hospira, Inc. ("Hospira") related to its 505(b)(2) new drug application ("NDA") referencing BENDEKA in the U.S. District Court for the District of Delaware. On December 16, 2019, the Delaware District Court dismissed the case against Hospira on all but one of the asserted patents, which expires in 2031. Trial against Hospira on that patent has been postponed and is scheduled to begin in April 2022.

In addition to the settlement with Eagle regarding its bendamustine 505(b)(2) NDA, between 2015 and 2020, we reached final settlements with 22 ANDA filers for generic versions of the lyophilized form of TREANDA and one 505(b)(2) NDA filer for a generic version of the liquid form of TREANDA, providing for the launch of generic versions of TREANDA prior to patent expiration.

COPAXONE revenues in our North America segment in the third quarter of 2021 decreased by 44% to \$133 million, compared to the third quarter of 2020, mainly due to generic competition in the United States.

The market for MS treatments continues to develop, particularly with the approval of generic versions of COPAXONE. Additionally, oral treatments for MS, such as Tecfidera®, Gilenya® and Aubagio®, continue to present significant and increasing competition. COPAXONE also continues to face competition from existing injectable products, as well as from monoclonal antibodies, such as Ocrevus®.

ProAir (HFA and RespiClick) revenues in our North America segment in the third quarter of 2021 were \$31 million, a decrease of 37% compared to the third quarter of 2020, mainly due to generic competition. In January 2019, we launched our own ProAir authorized generic in the United States, following the launch of a generic version of Ventolin® HFA, another albuterol inhaler. Revenues from our ProAir authorized generic are included in "generic products" above. During the third quarter of 2021, the exit market share of our overall albuterol product, including our ProAir authorized generic was 38%, making it the second largest in the market, compared to 44% in the third quarter of 2020. Other generic versions of ProAir were launched in 2020.

Anda revenues in our North America segment in the third quarter of 2021 increased by 7% to \$363 million, compared to \$341 million in the third quarter of 2020, mainly due to higher demand. Anda, our distribution business in the United States, distributes generic, specialty and OTC pharmaceutical products from various third party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda is able to compete in the secondary distribution market by maintaining high inventory levels for a broad offering of products, competitive pricing and offering next day delivery throughout the United States.

Product Launches and Pipeline

In the third quarter of 2021 we had no launches of generic versions of branded products in North America.

Our generic products pipeline in the United States includes, as of September 30, 2021, 201 product applications awaiting FDA approval, including 72 tentative approvals. This total reflects all pending ANDAs, supplements for product line extensions and tentatively approved applications and includes some instances where more than one application was submitted for the same reference product. Excluding overlaps, the branded products underlying these pending applications had U.S. sales for the twelve months ended June 30, 2021 of approximately \$108 billion, according to IQVIA. Approximately 72% of pending applications include a paragraph IV patent challenge, and we believe we are first to file with respect to 75 of these products, or 102 products including final approvals where launch is pending a settlement agreement or court decision. Collectively, these first to file opportunities represent over \$79 billion in U.S. brand sales for the twelve months ended June 30, 2021, according to IQVIA.

IQVIA reported brand sales are one of the many indicators of future potential value of a launch, but equally important are the mix and timing of competition, as well as cost effectiveness. The potential advantages of being the first filer with respect to some of these products may be subject to forfeiture, shared exclusivity or competition from so-called "authorized generics," which may ultimately affect the value derived.

In the third quarter of 2021, we received tentative approvals for generic equivalents of the products listed in the table below, excluding overlapping applications. A "tentative approval" indicates that the FDA has substantially completed its review of an application and final approval is expected once the relevant patent expires, a court decision is reached, a 30-month regulatory stay lapses or a 180-day exclusivity period awarded to another manufacturer either expires or is forfeited.

		Total Annual U.S. Branded Market (U.S. \$ in millions
Generic Name	Brand Name	(IQVIA))*
Methylnaltrexone Bromide Subcutaneous Injection	Relistor ®	\$ 18
Tasimelteon Caps	Hetlioz ®	\$ 1

* The figures presented are for the twelve months ended in the calendar quarter immediately prior to our launch or re-launch.

⁵³

We have additional biosimilar products in development in various stages of clinical trials and regulatory review worldwide, including phase 3 clinical trials for biosimilars to Prolia® (denosumab), Stelara® (ustekinumab) and Xolair® (omalizumab) and regulatory review for biosimilars to Humira® (adalimumab) and Lucentis® (ranibizumab).

Below is a description of key products in our specialty pipeline as of September 30, 2021:

	Phase 2	Phase 3	Pre-Submission	Under Regulatory Review
Novel Biologics	Fremanezumab Fibromyalgia
	TEV-48574 Respiratory	Fasinumab Osteoarthritic Pain (March 2016) (1)
	TEV-53275 Respiratory
Small Molecules	Deutetrabenazine Additional indication	Deutetrabenazine Dyskinesia in Cerebral Palsy (September 2019)		Risperidone LAI Schizophrenia (2)
Digital Respiratory			Digihaler® (budesonide and formoterol fumarate dihydrate) (EU)
			QVAR® Digihaler® (beclomethasone dipropionate HFA) (U.S.)

OA2, were released on August 5, 2020, indicating that the co-primary endpoints for fasinumab 1 mg monthly were achieved. Fasinumab 1 mg monthly demonstrated significant improvements in pain and physical function over placebo at week 16 and week 24, respectively. Fasinumab 1 mg monthly also showed nominally significant benefits in physical function in two trials and pain in one trial, when compared to the maximum FDA-approved prescription doses of non-steroidal anti-inflammatory drugs for osteoarthritis. The FACT OA1 trial included an additional treatment arm, fasinumab 1 mg every two months, which showed numerical benefit over placebo, but did not reach statistical significance. In initial safety analyses from the phase 3 trials, there was an increase in arthropathies reported with fasinumab. In a sub-group of patients from one phase 3 long-term safety trial, there was an increase in joint replacement with fasinumab 1 mg monthly treatment during the off-drug follow-up period, although this increase was not seen in the other trials to date.

Active treatment of patients with fasinumab, which only involved dosing in an optional second-year extension phase of one trial, has been discontinued following a recommendation from the fasinumab program's Independent Data Monitoring Committee that the program should be terminated, based on available evidence obtained to date. The core efficacy data has already been obtained to support potential fasinumab regulatory filings. Long-term safety data continues to be gathered, and is expected to be reported in 2021.

Currently, all non-essential activities and related expenditures for fasinumab have been put on hold. Next steps will be assessed together with Regeneron, with the intention of discussing data with the FDA.

• (2) Developed under a license agreement with MedinCell. In August 2021, the FDA accepted the NDA for risperidone LAI, based on phase 3 data from two pivotal studies.
  • 54

North America Gross Profit

Gross profit from our North America segment in the third quarter of 2021 was \$967 million, a decrease of 8%, compared to \$1,056 million in the third quarter of 2020. This decrease was mainly due to lower gross profit from COPAXONE.

Gross profit margin for our North America segment in the third quarter of 2021 decreased to 51.6%, compared to 52.4% in the third quarter of 2020. This decrease was mainly due to a change in the mix of products.

North America R&D Expenses

R&D expenses relating to our North America segment in the third quarter of 2021 were \$146 million, a decrease of 6%, compared to \$155 million in the third quarter of 2020.

For a description of our R&D expenses in the third quarter of 2021, see "—Teva Consolidated Results—Research and Development (R&D) Expenses" below.

North America S&M Expenses

S&M expenses relating to our North America segment in the third quarter of 2021 were \$250 million, flat compared to the third quarter of 2020.

North America G&A Expenses

G&A expenses relating to our North America segment in the third quarter of 2021 were \$121 million, an increase of 25%, compared to \$97 million in the third quarter of 2020.

North America Profit

Profit from our North America segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.

Profit from our North America segment in the third quarter of 2021 was \$458 million, a decrease of 18% compared to \$560 million in the third quarter of 2020, mainly due to lower gross profit.

Europe Segment

The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2021 and 2020:

		Three months ended September 30,
	2021		2020
		(U.S. \$ in millions / % of Segment Revenues)
Revenues	\$1,220	100%	\$1,116	100%
Gross profit	714	58.6%	637	57.1%
R&D expenses	55	4.5%	60	5.4%
S&M expenses	204	16.7%	200	17.9%
G&A expenses	64	5.2%	66	5.9%
Other income	(2)	§	(1)	§
Segment profit*	\$ 394	32.3%	\$ 312	28.0%

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than \$1 million or 0.5%, as applicable.

Europe Revenues

Our Europe segment includes the European Union and certain other European countries. Revenues from our Europe segment in the third quarter of 2021 were \$1,220 million, an increase of 9% or \$104 million, compared to the third quarter of 2020. In local currency terms, revenues increased by 6%, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

Revenues by Major Products and Activities

The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2021 and 2020:

		Three months ended September 30,		Percentage Change
				2021		2020
			(U.S. \$ in millions)		2020-2021
Generic products	\$	895	\$	824	9%
AJOVY		23		8	180%
COPAXONE		95		101	(6%)
Respiratory products		85		77	10%
Other		122		106	15%
Total		\$ 1,220	\$ 1,116		9%

Generic products revenues in our Europe segment in the third quarter of 2021, including OTC products, increased by 9% to \$895 million, compared to the third quarter of 2020. In local currency terms, revenues increased by 7%, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

AJOVY revenues in our Europe segment in the third quarter of 2021 increased to \$23 million, compared to \$8 million in the third quarter of 2020, mainly due to launches and reimbursements in additional European countries as well as growth in existing countries.

By the end of the third quarter of 2021, we launched AJOVY in most European countries and we are moving forward with plans to launch in other European countries. For information about AJOVY patent protection, see "—North America Revenues—Revenues by Major Product" above.

COPAXONE revenues in our Europe segment in the third quarter of 2021 decreased by 6% to \$95 million, compared to the third quarter of 2020. In local currency terms, revenues decreased by 7%, due to price reductions and a decline in volume resulting from competing glatiramer acetate products.

One European patent protecting COPAXONE 40 mg/mL was found invalid by the Board of Appeal of the European Patent Office in September 2020. Two additional patents expiring in 2030 are currently under opposition at the European Patent Office. In certain countries, Teva remains in litigation against generic companies on an additional COPAXONE 40 mg/mL patent that expires in 2030.

Respiratory products revenues in our Europe segment in the third quarter of 2021 increased by 10% to \$85 million compared to the third quarter of 2020. In local currency terms, revenues increased by 7%, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

Product Launches and Pipeline

As of September 30, 2021, our generic products pipeline in Europe included 436 generic approvals relating to 63 compounds in 132 formulations, with no European Medicines Agency ("EMA") approvals received. In addition, approximately 1,295 marketing authorization applications are pending approval in 37 European countries, relating to 130 compounds in 266 formulations. One application is pending with the EMA (for two strengths in 30 countries).

For information regarding our specialty pipeline, see "—North America Segment —Product Launches and Pipeline" above.

Europe Gross Profit

Gross profit from our Europe segment in the third quarter of 2021 was \$714 million, an increase of 12% compared to \$637 million in the third quarter of 2020, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns.

Gross profit margin for our Europe segment in the third quarter of 2021 increased to 58.6%, compared to 57.1% in the third quarter of 2020.

Europe R&D Expenses

R&D expenses relating to our Europe segment in the third quarter of 2021 were \$55 million, a decrease of 8% compared to \$60 million in the third quarter of 2020.

For a description of our R&D expenses in the third quarter of 2021, see "—Teva Consolidated Results—Research and Development (R&D) Expenses" below.

Europe S&M Expenses

S&M expenses relating to our Europe segment in the third quarter of 2021 were \$204 million, an increase of 2% compared to \$200 million in the third quarter of 2020. This increase was mainly due to exchange rate fluctuations, as well as lower expenses in the third quarter of 2020 attributed to restrictions related to the COVID-19 pandemic.

Europe G&A Expenses

G&A expenses relating to our Europe segment in the third quarter of 2021 were \$64 million, a decrease of 4% compared to \$66 million in the third quarter of 2020.

Europe Profit

Profit from our Europe segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.

Profit from our Europe segment in the third quarter of 2021 was \$394 million, an increase of 26%, compared to \$312 million in the third quarter of 2020. This increase was mainly due to higher revenues, as discussed above.

International Markets Segment

The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2021 and 2020:

		Three months ended September 30,
		2021		2020
		(U.S. \$ in millions / % of Segment Revenues)
Revenues	\$ 530	100%	\$ 529	100%
Gross profit	296	55.9%	275	52.0%
R&D expenses	16	3.0%	17	3.2%
S&M expenses	102	19.2%	101	19.1%
G&A expenses	29	5.4%	33	6.3%
Other income	(2)	§	(1)	§
Segment profit*	\$ 152	28.8%	\$ 125	23.6%

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than 0.5%.

International Markets Revenues

Our International Markets segment includes all countries in which we operate other than those in our North America and Europe segments. The International Markets segment includes more than 35 countries, covering a substantial portion of the global pharmaceutical market. Our key international markets are Japan, Russia and Israel. The countries in our International Markets segment include highly regulated, pure generic markets, such as Israel, branded generics oriented markets, such as Russia and certain Latin America markets and hybrid markets, such as Japan.

On February 1, 2021, we completed the sale of the majority of the generic and operational assets of our business venture in Japan.

Revenues from our International Markets segment in the third quarter of 2021 were \$530 million, flat compared to the third quarter of 2020. In local currency terms, revenues increased by 1% compared to the third quarter of 2020, mainly due to higher revenues in most markets and a milestone payment of \$35 million from Otsuka related to the launch of AJOVY in Japan, partially offset by lower revenues in Japan resulting from the divestment mentioned above, as well as regulatory price reductions and generic competition to off-patented products. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and on customer stocking and purchasing patterns.

Revenues by Major Products and Activities

The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2021 and 2020:

		Three months ended September 30,
	2021	2020 (U.S. \$ in millions)	2020-2021
Generic products	\$ 412	\$ 429	(4%)
AJOVY	39	16	145%
COPAXONE	10	14	(30%)
Other	69	71	(3%)
Total	\$ 530	\$ 529	§

Generic products revenues in our International Markets segment in the third quarter of 2021, which include OTC products, decreased by 4% in U.S. dollar or 3% in local currency terms, to \$412 million, compared to the third quarter of 2020. This decrease was mainly due to lower sales in Japan resulting from the divestment mentioned above, as well as regulatory price reductions and generic competition to off-patented products in Japan, partially offset by higher revenues in most other markets.

AJOVY was launched in certain markets in our International Markets segment, including in Japan during the third quarter of 2021. We are moving forward with plans to launch AJOVY in other markets. AJOVY revenues in our International Markets segment in the third quarter of 2021 were \$39 million, compared to \$16 million in the third quarter of 2020. Revenues in the third quarter of 2021 included a milestone payment of \$35 million received from Otsuka related to the launch of AJOVY in Japan. Revenues in the third quarter of 2020 included a milestone payment of \$15 million received from Otsuka.

COPAXONE revenues in our International Markets segment in the third quarter of 2021 were \$10 million compared to \$14 million in the third quarter of 2020.

AUSTEDO was launched in China for the treatment of chorea associated with Huntington disease and for the treatment of tardive dyskinesia in early 2021. We continue with additional submissions in various other markets.

International Markets Gross Profit

Gross profit from our International Markets segment in the third quarter of 2021 was \$296 million, an increase of 8% compared to \$275 million in the third quarter of 2020.

Gross profit margin for our International Markets segment in the third quarter of 2021 increased to 55.9%, compared to 52.0% in the third quarter of 2020. This increase was mainly due to the divestment in Japan mentioned above, the Otsuka milestone payment for AJOVY and a change in product portfolio mix, partially offset by regulatory price reductions and generic competition to off-patented products in Japan.

International Markets R&D Expenses

R&D expenses relating to our International Markets segment in the third quarter of 2021 were \$16 million, a decrease of 8% compared to \$17 million in the third quarter of 2020.

For a description of our R&D expenses in the third quarter of 2021, see "—Teva Consolidated Results—Research and Development (R&D) Expenses" below.

International Markets S&M Expenses

S&M expenses relating to our International Markets segment in the third quarter of 2021 were \$102 million, flat compared to the third quarter of 2020.

International Markets G&A Expenses

G&A expenses relating to our International Markets segment in the third quarter of 2021 were \$29 million, a decrease of 14% compared to \$33 million in the third quarter of 2020.

International Markets Profit

Profit from our International Markets segment consists of gross profit less R&D expenses, S&M expenses, G&A expenses and any other income related to this segment. Segment profit does not include amortization and certain other items.

Profit from our International Markets segment in the third quarter of 2021 was \$152 million, an increase of 22%, compared to \$125 million in the third quarter of 2020. This increase was mainly due to higher gross profit.

Other Activities

We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our North America, Europe or International Markets segments described above.

Our revenues from other activities in the third quarter of 2021 were \$262 million, a decrease of 17% compared to the third quarter of 2020 in both U.S. dollar and local currency terms, mainly due to a decrease in volumes from API and Medis resulting from the COVID-19 pandemic, as well as lower revenues from contract manufacturing services.

API sales to third parties in the third quarter of 2021 were \$161 million, a decrease of 8% in both U.S. dollar and local currency terms compared to the third quarter of 2020.

Teva Consolidated Results

Revenues

Revenues in the third quarter of 2021 were \$3,887 million, a decrease of 2%, or 3% in local currency terms, compared to the third quarter of 2020. This decrease was mainly due to lower revenues in our North America segment, mainly due to COPAXONE and generic products, partially offset by higher revenues from generic and OTC products in our Europe segment, AJOVY and AUSTEDO. Revenues continued to be affected by the ongoing impact of the COVID-19 pandemic on markets and on customer stocking and purchasing patterns. See "—North America Revenues," "—Europe Revenues," "—International Markets Revenues" and "—Other Activities" above.

Exchange rate movements during the third quarter of 2021, including hedging effects, positively impacted revenues by \$42 million, compared to the third quarter of 2020. See note 8c to our consolidated financial statements.

Gross Profit

Gross profit in the third quarter of 2021 was \$1,794 million, a decrease of 3% compared to the third quarter of 2020. This decrease was mainly a result of the factors discussed above under "—North America Gross Profit," "—Europe Gross Profit" and "—International Markets Gross Profit."

Gross profit margin was 46.2% in the third quarter of 2021, compared to 46.6% in the third quarter of 2020.

The decrease in gross profit margin was mainly driven by a change in the mix of products sold, resulting from lower sales of specialty products that have higher profitability, mainly COPAXONE, and lower profitability from Anda, partially offset by improved profitability from generic products, mainly in our North America segment.

Research and Development (R&D) Expenses

Our R&D activities for generic products in each of our segments include both (i) direct expenses relating to product formulation, analytical method development, stability testing, management of bioequivalence and other clinical studies and regulatory filings; and (ii) indirect expenses, such as costs of internal administration, infrastructure and personnel.

Our R&D activities for specialty and biosimilar products in each of our segments include costs of discovery research, preclinical development, early- and late-clinical development and drug formulation, clinical trials and product registration costs. These expenditures are reported net of contributions received from collaboration partners. Our spending takes place throughout the development process, including (i) early-stage projects in both discovery and preclinical phases; (ii) middle-stage projects in clinical programs up to phase 3; (iii) late-stage projects in phase 3 programs, including where a new drug application is currently pending approval; (iv) post-approval studies for marketed products; and (v) indirect expenses, such as costs of internal administration, infrastructure and personnel.

R&D expenses in the third quarter of 2021 were \$222 million, a decrease of 14% compared to the third quarter of 2020.

In the third quarter of 2021, our R&D expenses related primarily to specialty product candidates in the respiratory, pain, migraine and headache therapeutic areas, with additional activities in selected other areas and generic products including biosimilars.

Our lower R&D expenses in the third quarter of 2021, compared to the third quarter of 2020, were mainly due to a decrease in the pain and neuropsychiatry therapeutic areas as well as various generics projects.

R&D expenses as a percentage of revenues were 5.7% in the third quarter of 2021, compared to 6.5% in the third quarter of 2020.

Selling and Marketing (S&M) Expenses

S&M expenses in the third quarter of 2021 were \$597 million, a decrease of 1% compared to the third quarter of 2020.

S&M expenses as a percentage of revenues were 15.4% in the third quarter of 2021, compared to 15.2% in the third quarter of 2020.

General and Administrative (G&A) Expenses

G&A expenses in the third quarter of 2021 were \$291 million, an increase of 4% compared to the third quarter of 2020.

G&A expenses as a percentage of revenues were 7.5% in the third quarter of 2021, compared to 7.0% in the third quarter of 2020.

Intangible Asset Impairments

We recorded expenses of \$21 million for identifiable intangible asset impairments in the third quarter of 2021, compared to expenses of \$509 million in the third quarter of 2020. See note 5 to our consolidated financial statements.

Goodwill Impairment

In the third quarter of 2021, there were no goodwill impairment charges recorded, compared to a goodwill impairment charge of \$4,628 million in the third quarter of 2020, which was related to our North America reporting unit.

Other Asset Impairments, Restructuring and Other Items

We recorded expenses of \$62 million for other asset impairments, restructuring and other items in the third quarter of 2021, compared to income of \$98 million in the third quarter of 2020. For further details, as well as a description of significant regulatory and other events, see note 12 to our consolidated financial statements.

Legal Settlements and Loss Contingencies

In the third quarter of 2021, we recorded an expense of \$3 million in legal settlements and loss contingencies, compared to an expense of \$21 million in the third quarter of 2020. See note 9 to our consolidated financial statements.

Other Income

Other income in the third quarter of 2021 was \$25 million, compared to \$8 million in the third quarter of 2020.

Operating Income (Loss)

Operating income was \$623 million in the third quarter of 2021, compared to a loss of \$4,342 million in the third quarter of 2020.

Operating income as a percentage of revenues was 16.0% in the third quarter of 2021, compared to operating loss as a percentage of revenues of 109.1% in the third quarter of 2020. The operating loss in the third quarter of 2020 was mainly due to a goodwill impairment charge and higher intangible asset impairment charges.

Financial Expenses, Net

Financial expenses were \$241 million in the third quarter of 2021, compared to \$117 million in the third quarter of 2020. Financial expenses in the third quarter of 2021 were mainly comprised of interest expenses of \$232 million. Financial expenses in the third quarter of 2020 were mainly comprised of interest expenses of \$241 million, partially offset by gains on revaluations of marketable securities of \$124 million.

The following table presents a reconciliation of our segment profits to our consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended September 30, 2021 and 2020:

		Three months ended
		September 30,
	2021	2020
		(U.S. \$ in millions)
North America profit	\$ 458	\$ 560
Europe profit	394	312
International Markets profit	152	125
Total reportable segments profit	1,004	997
Profit of other activities	38	28
Total segments profit	1,042	1,025
Amounts not allocated to segments:
Amortization	199	251
Other assets impairments, restructuring and other items	62	(98)
Goodwill impairment	—	4,628
Intangible asset impairments	21	509
Legal settlements and loss contingencies	3	21
Other unallocated amounts	134	55
Consolidated operating income (loss)	623	(4,342)
Financial expenses, net	241	117
Consolidated income (loss) before income taxes	\$ 382	\$(4,459)

Tax Rate

In the third quarter of 2021, we recognized a tax expense of \$76 million, on pre-tax income of \$382 million. In the third quarter of 2020, we recognized a tax expense of \$16 million, on pre-tax loss of \$4,459 million. Our tax rate for the third quarter of 2021 was mainly affected by amortization and interest expense disallowance.

The statutory Israeli corporate tax rate is 23% in 2021. Our tax rate differs from the Israeli statutory tax rate, mainly due to generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, tax benefits in Israel and other countries, as well as infrequent or non-recurring items.

Share In (Profits) Losses of Associated Companies, Net

Share in losses of associated companies, net in the third quarter of 2021 was \$5 million, compared to share in profits of associated companies, net of \$136 million in the third quarter of 2020. The profit in the third quarter of 2020 was mainly due to a gain of \$134 million reflecting the difference between the book value of our investment in American Well Corporation and its fair value as of the date it completed its initial public offering in September 2020 (see note 16 to our consolidated financial statements).

Net Income (Loss) Attributable to Teva

Net income was \$292 million in the third quarter of 2021, compared to net loss of \$4,349 million in the third quarter of 2020. The loss in the third quarter of 2020 was mainly due to a goodwill impairment charge and intangible asset impairment charges.

Diluted Shares Outstanding and Earnings (Loss) per Share

The weighted average diluted shares outstanding used for the fully diluted share calculation for the three months ended September 30, 2021 and 2020 were 1,109 million and 1,096 million shares, respectively.

In computing diluted earnings per share for the three months ended September 30, 2021 basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.

In computing diluted loss per share for the three months ended September 30, 2020, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.

Diluted earnings per share were \$0.26 in the third quarter of 2021, compared to diluted loss per share of \$3.97 in the third quarter of 2020.

Share Count for Market Capitalization

We calculate share amounts using the outstanding number of shares (i.e., excluding treasury shares) plus shares that would be outstanding upon the exercise of options and vesting of RSUs and performance share units and the conversion of our convertible senior debentures, in each case, at period end.

As of September 30, 2021 and 2020, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,128 million and 1,118 million, respectively.

Impact of Currency Fluctuations on Results of Operations

In the third quarter of 2021, approximately 48% of our revenues were denominated in currencies other than the U.S. dollar. Because our results are reported in U.S. dollars, we are subject to significant foreign currency risks. Accordingly, changes in the rate of exchange between the U.S. dollar and the local currencies in the markets in which we operate (primarily the euro, British pound, Japanese yen, new Israeli shekel, Canadian dollar and Russian ruble) impact our results.

During the third quarter of 2021, the following main currencies relevant to our operations decreased in value against the U.S. dollar (each on a quarterly average compared to quarterly average basis): Argentinian peso by 25%, Turkish lira by 16%, Japanese yen by 4% and Polish zloty by 2%. The following main currencies relevant to our operations increased in value against the U.S. dollar: Mexican peso by 10%, British pound by 7%, Canadian dollar by 6% and Israeli shekel by 6%.

As a result, exchange rate movements during the third quarter of 2021, including hedging effects, positively impacted overall revenues by \$42 million and operating income by \$22 million, compared to the third quarter of 2020.

In the third quarter of 2021, a positive hedging impact of \$16 million was recognized under revenues, and a minimal negative impact was recognized under cost of sales. In the third quarter of 2020, a negative hedging impact of \$4 million was recognized under revenues and a negative impact of \$2 million was recognized under cost of sales.

Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 8c to our consolidated financial statements.

Commencing in the third quarter of 2018, the cumulative inflation in Argentina exceeded 100% or more over a three-year period. Although this triggered highly inflationary accounting treatment, it did not have a material impact on our results of operations.

Comparison of Nine Months Ended September 30, 2021 to Nine Months Ended September 30, 2020

Unless specified otherwise, the factors used to explain quarterly changes on a year-over-year basis are also relevant for the comparison of the results for the nine months ended September 30, 2021 and 2020. Where there are different factors affecting the nine months comparison, we have described them below.

Segment Information

North America Segment

The following table presents revenues, expenses and profit for our North America segment for the nine months ended September 30, 2021 and 2020:

		Nine months ended September 30,
	2021			2020
		(U.S. \$ in millions / % of Segment Revenues)
Revenues	\$5,807	100%	\$6,146	100%
Gross profit	3,081	53.1%	3,208	52.2%
R&D expenses	467	8.1%	455	7.4%
S&M expenses	734	12.6%	755	12.3%
G&A expenses	338	5.8%	325	5.3%
Other income	(14)	§	(9)	§
Segment profit*	\$1,556	26.8%	\$1,682	27.4%

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than 0.5%.

North America Revenues

Our North America segment includes the United States and Canada. Revenues from our North America segment in the first nine months of 2021 were \$5,807 million, a decrease of 5.5% compared to \$6,146 million in the first nine months of 2020.

Revenues by Major Products and Activities

The following table presents revenues for our North America segment by major products and activities for the nine months ended September 30, 2021 and 2020:

		Nine months ended September 30,
	2021	2020 (U.S. \$ in millions)	Change 2020-2021
Generic products	\$2,864	\$2,804	2%
AJOVY	123	98	25%
AUSTEDO	520	451	15%
BENDEKA/TREANDA	292	313	(7%)
COPAXONE	448	671	(33%)
ProAir*	140	175	(20%)
Anda	968	1,141	(15%)
Other	451	493	(8%)
Total	\$5,807	\$6,146	(6%)

* Does not include revenues from our ProAir authorized generic, which are included under generic products.

North America Gross Profit

Gross profit from our North America segment in the first nine months of 2021 was \$3,081 million, a decrease of 4%, compared to \$3,208 million in the first nine months of 2020.

Gross profit margin for our North America segment in the first nine months of 2021 increased to 53.1% compared to 52.2% in the first nine months of 2020. This increase was mainly due to a change in the mix of products.

North America R&D Expenses

R&D expenses relating to our North America segment in the first nine months of 2021 were \$467 million, an increase of 3%, compared to \$455 million in the first nine months of 2020.

North America S&M Expenses

S&M expenses relating to our North America segment in the first nine months of 2021 were \$734 million, a decrease of 2.8% compared to \$755 million in the first nine months of 2020. This decrease was mainly due to lower S&M expenses related to Anda and additional efficiency measures.

North America G&A Expenses

G&A expenses relating to our North America segment in the first nine months of 2021 were \$338 million, an increase of 4%, compared to \$325 million in the first nine months of 2020.

North America Profit

Profit from our North America segment in the first nine months of 2021 was \$1,556 million, a decrease of 8%, compared to \$1,682 million in the first nine months of 2020.

Europe Segment

The following table presents revenues, expenses and profit for our Europe segment for the nine months ended September 30, 2021 and 2020:

Nine months ended September 30,
		2020
(U.S. \$ in millions / % of Segment
\$3,618	100%	\$3,520	100%
2,063	57.0%	2,009	57.1%
184	5.1%	180	5.1%
628	17.3%	590	16.8%
180	5.0%	184	5.2%
(3)	§	(3)	§
\$1,074	29.7%	\$1,058	30.1%
		2021	Revenues)

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than 0.5%.

Europe Revenues

Our Europe segment includes the European Union and certain other European countries. Revenues from our Europe segment in the first nine months of 2021 were \$3,618 million, an increase of 3% or \$98 million, compared to the first nine months of 2020. In local currency terms, revenues decreased by 3%, compared to the first nine months of 2020, mainly due to the impact the COVID-19 pandemic had on markets and on customer stocking and purchasing patterns, as well as lower revenues from COPAXONE, partially offset by higher revenues from AJOVY.

Revenues by Major Products and Activities

The following table presents revenues for our Europe segment by major products and activities for the nine months ended September 30, 2021 and 2020:

		Nine months ended September 30,	Percentage Change
	2021	2020	2020-2021
		(U.S. \$ in millions)
Generic products	\$2,637	\$ 2,593	2%
AJOVY	58	17	232%
COPAXONE	296	294	1%
Respiratory products	263	263	§
Other	364	352	3%
Total	\$3,618	\$ 3,520	3%

§ Represents an amount less than 0.5%.

Europe Gross Profit

Gross profit from our Europe segment in the first nine months of 2021 was \$2,063 million, an increase of 3% compared to \$2,009 million in the first nine months of 2020.

Gross profit margin for our Europe segment in the first nine months of 2021 decreased to 57.0% compared to 57.1% in the first nine months of 2020, mainly due to a change in the mix of products.

Europe R&D Expenses

R&D expenses relating to our Europe segment in the first nine months of 2021 were \$184 million, an increase of 2% compared to \$180 million in the first nine months of 2020.

Europe S&M Expenses

S&M expenses relating to our Europe segment in the first nine months of 2021 were \$628 million, an increase of 6% compared to \$590 million in the first nine months of 2020.

Europe G&A Expenses

G&A expenses relating to our Europe segment in the first nine months of 2021 were \$180 million, a decrease of 2% compared to \$184 million in the first nine months of 2020.

Europe Profit

Profit from our Europe segment in the first nine months of 2021 was \$1,074 million, an increase of 2% compared to the first nine months of 2020.

International Markets Segment

The following table presents revenues, expenses and profit for our International Markets segment for the nine months ended September 30, 2021 and 2020:

		2021	2020
		(U.S. \$ in millions / % of Segment Revenues)
Revenues	\$1,505	100%	\$1,582	100%
Gross profit	826	54.9%	828	52.3%
R&D expenses	51	3.4%	51	3.3%
S&M expenses	303	20.1%	312	19.7%
G&A expenses	79	5.3%	96	6.1%
Other (income) expense	(5)	§	(10)	(0.6%)
Segment profit*	\$ 398	26.4%	\$ 378	23.9%

* Segment profit does not include amortization and certain other items.

§ Represents an amount less than 0.5%.

International Markets Revenues

Our International Markets segment includes all countries other than those in our North America and Europe segments. Revenues from our International Markets segment in the first nine months of 2021 were \$1,505 million, a decrease of \$77 million, or 5%, compared to the first nine months of 2020. In local currency terms, revenues decreased by 3%. Revenues in the first nine months of 2021, included \$4 million from a positive hedging impact, compared to \$25 million from a positive hedging impact in the first nine months of 2020, which are included in "Other" in the table below. See note 8c to our consolidated financial statements.

Revenues by Major Products and Activities

The following table presents revenues for our International Markets segment by major products and activities for the nine months ended September 30, 2021 and 2020:

		Nine months ended September 30,	Percentage Change
	2021	2020	2020-2021
		(U.S. \$ in millions)
Generic products	\$1,211	\$1,304	(7%)
AJOVY	46	17	170%
			(23%)
	219	224	(2%)
	\$1,505	\$1,582	(5%)
COPAXONE	29	38

International Markets Gross Profit

Gross profit from our International Markets segment in the first nine months of 2021 was \$826 million, compared to \$828 million in the first nine months of 2020.

Gross profit margin for our International Markets segment in the first nine months of 2021 increased to 54.9%, compared to 52.3% in the first nine months of 2020.

International Markets R&D Expenses

R&D expenses relating to our International Markets segment in the first nine months of 2021 were \$51 million, flat compared to the first nine months of 2020.

International Markets S&M Expenses

S&M expenses relating to our International Markets segment in the first nine months of 2021 were \$303 million, a decrease of 3% compared to \$312 million in the first nine months of 2020.

International Markets G&A Expenses

G&A expenses relating to our International Markets segment in the first nine months of 2021 were \$79 million, a decrease of 17% compared to \$96 million in the first nine months of 2020.

International Markets Profit

Profit from our International Markets segment in the first nine months of 2021 was \$398 million, an increase of 5%, compared to \$378 million in the first nine months of 2020.

Other Activities

Our revenues from other activities in the first nine months of 2021 decreased by 11% to \$849 million, compared to the first nine months of 2020. In local currency terms, revenues decreased by 13%.

API sales to third parties in the first nine months of 2021 were \$537 million, a decrease of 5% in both U.S. dollar and local currency terms, compared to the first nine months of 2020.

Teva Consolidated Results

Revenues

Revenues in the first nine months of 2021 were \$11,778 million, a decrease of 4%, or 6% in local currency terms, compared to the first nine months of 2020.

Exchange rate movements during the first nine months of 2021, including hedging effects, positively impacted revenues by \$251 million, compared to the first nine months of 2020. See note 8c to our consolidated financial statements.

Gross Profit

Gross profit in the first nine months of 2021 was \$5,544 million, a decrease of 2% compared to the first nine months of 2020.

Gross profit margin was 47.1% in the first nine months of 2021, compared to 46.5% in the first nine months of 2020. This increase was mainly driven by a change in the mix of products sold, resulting from improved profitability from generic products, mainly in our North America segment, partially offset by lower sales of COPAXONE and lower profitability from Anda.

Research and Development (R&D) Expenses

R&D expenses in the first nine months of 2021 were \$723 million, an increase of 3% compared to the first nine months of 2020. Our higher R&D expenses in the first nine months of 2021, compared to the first nine months of 2020, were mainly due to an increase in respiratory and biosimilar projects as well as various generics projects, partially offset by lower expenses in the pain and neuropsychiatry therapeutic areas.

R&D expenses as a percentage of revenues were 6.1% in the first nine months of 2021, compared to 5.8% in the first nine months of 2020.

Selling and Marketing (S&M) Expenses

S&M expenses in the first nine months of 2021 were \$1,798 million, a decrease of 1% compared to the first nine months of 2020.

S&M expenses as a percentage of revenues were 15.3% in the first nine months of 2021, compared to 14.9% in the first nine months of 2020.

General and Administrative (G&A) Expenses

G&A expenses in the first nine months of 2021 were \$822 million, a decrease of 3% compared to the first nine months of 2020.

G&A expenses as a percentage of revenues were 7.0% in the first nine months of 2021, compared to 6.9% in the first nine months of 2020.

Intangible Asset Impairments

We recorded expenses of \$295 million for identifiable intangible asset impairments, in the first nine months of 2021, compared to expenses of \$1,278 million in the first nine months of 2020. See note 5 to our consolidated financial statements.

Goodwill Impairment

No goodwill impairment charges were recorded in the first nine months of 2021, compared to a goodwill impairment charge of \$4,628 million in the first nine months of 2020, which was related to our North America reporting unit.

Other Asset Impairments, Restructuring and Other Items

We recorded expenses of \$227 million for other asset impairments, restructuring and other items in the first nine months of 2021, compared to expenses of \$404 million in the first nine months of 2020. See note 12 to our consolidated financial statements.

Legal Settlements and Loss Contingencies

In the first nine months of 2021, we recorded expenses of \$113 million in legal settlements and loss contingencies, compared to an expense of \$10 million in the first nine months of 2020. See note 9 to our consolidated financial statements.

Other Income

Other income in the first nine months of 2021 was \$73 million, compared to \$30 million in the first nine months of 2020. The other income in the first nine months of 2021 was mainly due to capital gains related to the sale of certain OTC assets.

Operating Income (Loss)

Operating income was \$1,638 million in the first nine months of 2021, compared to operating loss of \$3,978 million in the first nine months of 2020.

Operating income as a percentage of revenues was 13.9% in the first nine months of 2021, compared to operating loss as a percentage of revenues of 32.6% in the first nine months of 2020.

Financial Expenses, Net

Financial expenses were \$805 million in the first nine months of 2021, compared to \$565 million in the first nine months of 2020. Financial expenses in the first nine months of 2021 were mainly comprised of interest expenses of \$711 million and loss on revaluations of marketable securities of \$104 million. Financial expenses in the first nine months of 2020 were mainly comprised of interest expenses of \$722 million, partially offset by gains on revaluations of marketable securities of \$118 million as well as a gain of \$27 million resulting from our hedging and derivatives activities.

The following table presents a reconciliation of our segment profits to our consolidated operating income (loss) and to consolidated income (loss) before income taxes for the nine months ended September 30, 2021 and 2020:

		Nine months ended September 30,
	2021	2020 (U.S. \$ in millions)
North America profit	\$1,556	\$1,682
Europe profit	1,074	1,058
International Markets profit	398	378
Total reportable segments profit	3,028	3,118
Profit of other activities	125	130
Total segments profit	3,153	3,248
Amounts not allocated to segments:
Amortization	613	758
Other assets impairments, restructuring and other items	227	404
Goodwill impairment	—	4,628

Intangible asset impairments	295	1,278
Legal settlements and loss contingencies	113	10
Other unallocated amounts	266	148
Consolidated operating income (loss)	1,638	(3,978)
Financial expenses, net	805	565
Consolidated income (loss) before income taxes	\$ 833	\$(4,543)

Tax Rate

In the first nine months of 2021, we recognized a tax expense of \$235 million, on pre-tax income of \$833 million. In the first nine months of 2020, we recognized a tax benefit of \$147 million, on pre-tax loss of \$4,543 million. Our tax rate in the first nine months of 2021 was mainly affected by amortization, impairments, legal settlements and interest expense disallowance.

Share in (Profits) Losses of Associated Companies, Net

Share in profits of associated companies, net in the first nine months of 2021 was \$9 million, compared to \$135 million in the first nine months of 2020. The profit in the first nine months of 2020 was mainly due to a gain of \$134 million reflecting the difference between the book value of our investment in American Well Corporation and its fair value as of the date it completed its initial public offering in September 2020 (see note 16 to our consolidated financial statements).

Net Income (Loss) Attributable to Teva

Net income was \$576 million in the first nine months of 2021, compared to net loss of \$4,140 million in the first nine months of 2020.

Diluted Shares Outstanding and Earnings (Loss) per Share

The weighted average diluted shares outstanding used for the fully diluted share calculation for the nine months ended September 30, 2021 and 2020 was 1,109 million shares and 1,095 million shares, respectively.

In computing diluted earnings per share for the nine months ended September 30, 2021, basic earnings per share were adjusted to take into account the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans. No account was taken of the potential dilution by the convertible senior debentures, since they had an anti-dilutive effect on earnings per share.

In computing diluted loss per share for the nine months ended September 30, 2020, no account was taken of the potential dilution that could occur upon the exercise of options and non-vested RSUs granted under employee stock compensation plans, and convertible senior debentures, since they had an anti-dilutive effect on loss per share.

Diluted earnings per share were \$0.52 in the first nine months of 2021, compared to diluted loss per share of \$3.78 in the first nine months of 2020.

Impact of Currency Fluctuations on Results of Operations

In the first nine months of 2021, approximately 48% of our revenues were denominated in currencies other than the U.S. dollar. Because our results are reported in U.S. dollars, we are subject to significant foreign currency risks and, accordingly, changes in the exchange rate between the U.S. dollar and local currencies in markets in which we operate (primarily the euro, British pound, Japanese yen, Israeli shekel, Canadian dollar and Russian ruble) impact our results.

During the first nine months of 2021, the following main currencies relevant to our operations decreased in value against the U.S. dollar: Argentinian peso by 28%, Turkish lira by 17%, Brazilian real by 6%, Russian ruble by 5% and Ukrainian hryvnia by 4% (all compared on a nine-month average basis). The following main currencies relevant to our operations increased in value against the U.S. dollar: Australian dollar by 12%, Swedish krona by 11%, Chilean peso by 9%, British pound by 9%, Canadian dollar by 8%, new Israeli shekel by 7%, Mexican peso by 7% and euro by 6%.

As a result, exchange rate movements during the first nine months of 2021 positively impacted overall revenues by \$251 million and our operating income by \$35 million, in comparison to the first nine months of 2020.

In the first nine months of 2021, a positive hedging impact of \$28 million was recognized under revenues, and a negative impact of \$1 million was recognized under cost of sales. In the first nine months of 2020, a positive hedging impact of \$37 million was recognized under revenues and a positive impact of \$3 million was recognized under cost of sales.

Hedging transactions against future projected revenues and expenses are recognized on the balance sheet at their fair value on a quarterly basis, while the foreign exchange impact on the underlying revenues and expenses may occur in subsequent quarters. See note 8c to our consolidated financial statements.

Liquidity and Capital Resources

Total balance sheet assets were \$47,851 million as of September 30, 2021, compared to \$49,195 million as of June 30, 2021.

Our working capital balance, which includes accounts receivables net of SR&A, inventories, prepaid expenses and other current assets, accounts payables, employee-related obligations, accrued expenses and other current liabilities, was \$968 million as of September 30, 2021, compared to \$1,196 million as of June 30, 2021. This decrease was mainly due to a decrease in our accounts receivables (net of SR&A) balances as a result of favorable collection of payments in North America.

Cash investment in property, plant and equipment in the third quarter of 2021 was \$146 million, compared to \$113 million in the second quarter of 2021. Depreciation in both the third and second quarters of 2021 was \$132 million.

Cash and cash equivalents and short-term and long-term investments as of September 30, 2021 were \$2,072 million, compared to \$2,479 million as of June 30, 2021. The decrease in the third quarter of 2021 was mainly due to repayment of our \$1,475 million 2.2% senior notes at maturity, partially offset by cash flow generated during the quarter and \$300 million borrowed under our unsecured syndicated revolving credit facility.

Our cash on hand that is not used for ongoing operations is generally invested in bank deposits as well as liquid securities that bear fixed and floating rates.

Our principal sources of short-term liquidity are our cash on hand, existing cash investments, liquid securities and available credit facilities, primarily our \$2.3 billion unsecured syndicated revolving credit facility entered into in April 2019 ("RCF").

The RCF agreement provides for two separate tranches, a \$1.15 billion tranche A and a \$1.15 billion tranche B. Tranche A has a maturity date of April 8, 2022, of which an amount of \$1.065 billion was extended twice, initially to April 8, 2023 and then to April 8, 2024. Tranche B has a maturity date of April 8, 2024. Loans and letters of credit will be available from time to time under each tranche for Teva's general corporate purposes.

The RCF contains certain covenants, including certain limitations on incurring liens and indebtedness and maintenance of certain financial ratios, including the requirement to maintain compliance with a net debt to EBITDA ratio, which becomes more restrictive over time. The net debt to EBITDA ratio limit is 5.00x in the third and fourth quarters of 2021, gradually declines to 4.50x in the first and second quarters of 2022, and continues to gradually decline over the remaining term of the RCF to 3.50x in the first quarter of 2023.

The RCF can be used for general corporate purposes, including repaying existing debt. As of September 30, 2021, \$300 million was outstanding under the RCF. As of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF.

Based on current and forecasted results, we expect that we will not exceed the financial covenant thresholds set forth in the RCF within one year from the date the financial statements are issued.

Under specified circumstances, including non-compliance with any of the covenants described above and the unavailability of any waiver, amendment or other modification thereto, we will not be able to borrow under the RCF. Additionally, violations of the covenants, under the abovementioned circumstances, would result in an event of default in all borrowings under the RCF and, when greater than a specified threshold amount as set forth in each series of senior notes is outstanding, could lead to an event of default under our senior notes due to cross acceleration provisions.

We expect that we will continue to have sufficient cash resources to support our debt service payments and all other financial obligations within one year from the date that the financial statements are issued.

Debt Balance and Movements

As of September 30, 2021, our debt was \$23,746 million, compared to \$25,132 million as of June 30, 2021. This decrease was mainly due to repayment of our \$1,475 million 2.2% senior notes at maturity and exchange rate fluctuations, partially offset by \$300 million borrowed under the RCF.

In July 2021, we repaid \$1,475 million of our 2.2% senior notes at maturity.

During the third quarter of 2021, we borrowed \$500 million under our RCF and repaid \$200 million of such borrowings. As of September 30, 2021, \$300 million was outstanding under the RCF. As of the date of this Quarterly Report on Form 10-Q, no amounts were outstanding under the RCF.

Our debt as of September 30, 2021 was effectively denominated in the following currencies: 63% in U.S. dollars, 34% in euros and 3% in Swiss francs.

The portion of total debt classified as short-term as of September 30, 2021 was 11%, compared to 14% as of June 30, 2021.

Our financial leverage was 67% as of September 30, 2021, compared to 69% as of June 30, 2021.

Our average debt maturity was approximately 5.4 years as of September 30, 2021, compared to 5.3 years as of June 30, 2021.

Total Equity

Total equity was \$11,451 million as of September 30, 2021, compared to \$11,311 million as of June 30, 2021. This increase was mainly due to net income of \$302 million, partially offset by a negative impact of \$195 million from exchange rate fluctuations.

Exchange rate fluctuations affected our balance sheet, as approximately 56% of our net assets in the third quarter of 2021 (including both non-monetary and monetary assets) were in currencies other than the U.S. dollar. When compared to June 30, 2021, changes in currency rates had a negative impact of \$195 million on our equity as of September 30, 2021, mainly due to the changes in value against the U.S. dollar of: the Chilean peso by 11%, the Peruvian sol by 6%, the Polish zloty by 5%, the Mexican peso by 3%, the Canadian dollar by 3%, the euro by 3%, the British pound by 3% and the Croatian kuna by 3%. All comparisons are on a quarter-end to quarter-end basis.

Cash Flow

We seek to continually improve the efficiency of our working capital management. From time to time, as part of our cash management activities, we may make decisions in our commercial and supply chain activities which may drive an acceleration of receivable payments from customers or deceleration of payments to vendors, having the effect of increasing or decreasing cash from operations in an individual period. Such decisions had no material impact on our year-to-date operating cash flow measurement, but may impact quarter-to-quarter results.

Cash flow generated from operating activities during the third quarter of 2021 was \$529 million, compared to \$307 million in the third quarter of 2020. The increase in the third quarter of 2021 was mainly due to favorable collection of payments from customers in North America.

During the third quarter of 2021, we generated free cash flow of \$795 million, which we define as comprising \$529 million in cash flow generated from operating activities, \$397 million in beneficial interest collected in exchange for securitized accounts receivables and \$15 million in proceeds from divestitures of businesses and other assets, partially offset by \$146 million in cash used for capital investment. During the third quarter of 2020, we generated free cash flow of \$506 million, comprising \$307 million in cash flow generated from operating activities, \$333 million in beneficial interest collected in exchange for securitized accounts receivables and \$9 million in proceeds from sale of property, plant and equipment and intangible assets, partially offset by \$143 million in cash used for capital investment. The increase in the third quarter of 2021 resulted mainly from higher cash flow from operating activities.

Dividends

We have not paid dividends on our ordinary shares or ADSs since December 2017.

Commitments

In addition to financing obligations under short-term debt and long-term senior notes and loans, debentures and convertible debentures, our major contractual obligations and commercial commitments include leases, royalty payments, contingent payments pursuant to acquisition agreements and participation in joint ventures associated with R&D activities.

In October 2021, we announced a license agreement with MODAG GmbH ("Modag"), that will provide Teva an exclusive global license to develop, manufacture and commercialize Modag's lead compound anle138b and a related compound (sery433). The agreement is subject to regulatory approval. Anle138b was initially developed for the treatment of Multiple System Atrophy (MSA) and Parkinson's disease, and has the potential to be applied to other treatments for neurodegenerative disorders, such as Alzheimer's disease. A phase 1b clinical trial is currently being completed. Teva will make an upfront payment subject to regulatory approval and Modag may be eligible for future development milestone payments, totaling an aggregate amount of up to \$80 million, as well as future commercial milestones and royalties.

In August 2020, we entered into an agreement with biopharmaceutical company Alvotech for the exclusive commercialization in the U.S. of five biosimilar product candidates. The initial pipeline for this collaboration contains biosimilar candidates addressing multiple therapeutic areas, including a proposed biosimilar to Humira®. Under this agreement, Alvotech is responsible for the development, registration and supply of the biosimilar product candidates and Teva will exclusively commercialize the products in the United States. We paid an upfront payment in the third quarter of 2020 and additional upfront and milestone payments in the second quarter of 2021 that were recorded as R&D expenses. Additional development and commercial milestone payments of up to \$450 million, as well as royalty payments, may be payable by Teva over the next few years. Teva and Alvotech will share profit from the commercialization of these biosimilars. In March 2021, Abbvie sued Alvotech for allegedly misappropriating confidential information relating to Humira®. In October 2021, the federal court dismissed the lawsuit for lack of jurisdiction. In addition, there is pending patent litigation between Abbvie and Alvotech related to Alvotech's proposed biosimilar to Humira®.

In September 2016, we entered into a collaborative agreement with Regeneron to develop and commercialize Regeneron's pain medication product, fasinumab. We share in the global commercial rights to this product with Regeneron (excluding Japan, Korea and nine other Asian countries), as well as ongoing associated R&D costs of approximately \$1 billion. We made an upfront payment of \$250 million to Regeneron in the third quarter of 2016 and additional payments for achievement of development milestones in an aggregate amount of \$120 million were paid during 2017 and 2018. The agreement stipulates additional development and commercial milestone payments of up to \$2,230 million, as well as future royalties. For information regarding fasinumab, see "—North America Segment —Product Launches and Pipeline" above.

In October 2016, we entered into a collaborative agreement with Celltrion to commercialize Truxima and Herzuma, two biosimilar products for the U.S. and Canadian markets. We paid Celltrion \$160 million, of which we received an aggregate credit of \$60 million as of March 31, 2021. We share the profit from the commercialization of these products with Celltrion. These two products, Truxima and Herzuma, were approved by the FDA in November and December 2018, respectively and were launched in the United States in November 2019 and March 2020, respectively. No additional milestone payments are expected.

In November 2013, we entered into an agreement with MedinCell for the development and commercialization of multiple long-acting injectable products. The lead product candidate selected was risperidone LAI (TV-46000) suspension for subcutaneous use for the treatment of schizophrenia. In August 2021, the FDA accepted the NDA for risperidone LAI, based on phase 3 data from two pivotal studies. We lead the clinical development and regulatory process and are responsible for commercialization of this product candidate. MedinCell may be eligible for development milestones, and future commercial milestones of up to \$112 million in respect of risperidone LAI. We will also pay MedinCell royalties on net sales.

We are committed to pay royalties to owners of know-how, partners in alliances and certain other arrangements, and to parties that financed R&D at a wide range of rates as a percentage of sales of certain products, as defined in the agreements. In some cases, the royalty period is not defined; in other cases, royalties will be paid over various periods not exceeding 20 years.

In connection with certain development, supply and marketing, and research and collaboration or services agreements, we are required to indemnify, in unspecified amounts, the parties to such agreements against third-party claims relating to (i) infringement or violation of intellectual property or other rights of such third party; or (ii) damages to users of the related products. Except as described in our financial statements, we are not aware of any material pending action that may result in the counterparties to these agreements claiming such indemnification.

2021 Aggregated Contractual Obligations

There have not been any material changes in our assessment of material contractual obligations and commitments as set forth in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020.

Supplemental Non-GAAP Income Data

We utilize certain non-GAAP financial measures to evaluate performance, in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures:

• our management and Board of Directors use the non-GAAP measures to evaluate our operational performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management;
• our annual budgets are prepared on a non-GAAP basis; and
  • senior management's annual compensation is derived, in part, using these non-GAAP measures. While qualitative factors and judgment also affect annual bonuses, the principal quantitative element in the determination of such bonuses is performance targets tied to the work plan, which is based on the non-GAAP presentation set forth below.

Non-GAAP financial measures have no standardized meaning and accordingly have limitations in their usefulness to investors. We provide such non-GAAP data because management believes that such data provide useful information to investors. However, investors are cautioned that, unlike financial measures prepared in accordance with U.S. GAAP, non-GAAP measures may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses our performance. The limitations of using non-GAAP financial measures as performance measures are that they provide a view of our results of operations without including all events during a period and may not provide a comparable view of our performance to other companies in the pharmaceutical industry.

Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

In arriving at our non-GAAP presentation, we exclude items that either have a non-recurring impact on the income statement or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not singled out, potentially cause investors to extrapolate future performance from an improper base. In addition, we also exclude equity compensation expenses to facilitate a better understanding of our financial results, since we believe that such exclusion is important for understanding the trends in our financial results and that these expenses do not affect our business operations. While not all inclusive, examples of these items include:

• amortization of purchased intangible assets;
• legal settlements and/or loss contingencies, due to the difficulty in predicting their timing and scope;
• impairments of long-lived assets, including intangibles, property, plant and equipment and goodwill;
  • restructuring expenses, including severance, retention costs, contract cancellation costs and certain accelerated depreciation expenses primarily related to the rationalization of our plants or to certain other strategic activities, such as the realignment of R&D focus or other similar activities;
  • acquisition- or divestment- related items, including changes in contingent consideration, integration costs, banker and other professional fees, inventory step-up and IPR&D acquired in development arrangements;
• expenses related to our equity compensation;
• significant one-time financing costs and marketable securities investment valuation gains/losses;
• unusual tax items;

• other awards or settlement amounts, either paid or received;

• other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as impacts due to changes in accounting, significant costs for remediation of plants, such as inventory write-offs or related consulting costs, or other unusual events; and

• corresponding tax effects of the foregoing items.

The following tables present supplemental non-GAAP data, in U.S. dollar, which we believe facilitates an understanding of the factors affecting our business. In these tables, we exclude the following amounts:

applicable periods: The following table presents the GAAP measures, related non-GAAP adjustments and the corresponding non-GAAP amounts for the

				U. S. \$ a	Th nd ree sh are M on s in ths m En	illi on de d S s (e ept xce em pt	pe be r 3 r s ha 0, 2 re 02 am 1 ou	nts )
	GA AP				Ex clu ded fo r n on	-G AA P m eas	ure me nt				No n-G AA P
						Co sts
		Am ort iza tio n	Le gal	Im pai rm ent		reg rel ula ate d t tor o y
		of int pu ang rch ibl ase e d	set and tle lo me ss nts	of liv lon ets ed g	Re stru ctu rin g	tak act en ion in s	Eq uit y	Co nti ng ent	no n-G Oth AA er P	Oth er
Ne t re ven ue s	3,8 87	ass ets	con tin gen cie s	ass	cos ts	fac ilit ies	com pen sat ion	con sid era tio n	item s*	item s	3,8 87
Co st o f sa les	2,0 93	175				5	5		104		1,8 04
Gr oss pr ofi t	1,7 94	175				5	5		104		2,0 83
Gr oss pr ofi t m arg in	46 .2%										53 .6%
R& D exp ens es	22 2						4				21 7
G& S& M A e exp ens ens es es	29 597 1	24					10 7		6		27 567 5
Oth er inc xp om e	(25 )								(7)		(18 )
Le gal se ttle me nts an d l oss
con tin gen cie s	3		3								—
Oth res er tru ass ctu ets rin im g a pai nd rm ot ent her s,
item s	62			26	28			9	(1)		—
Int ang ibl e a sse ts i mp air me nts	21			21							—
Op era tin g i nco me (lo ss)	62 3	199	3	47	28	5	26	9	103		1,0 42
Fin anc ial exp ens es, ne t	24 1									6	23 5
Inc tax om es e ( los s) b efo re inc om e	382	199	3	47	28	5	26	9	103	6	807
Inc om e ta xes	76									(62 )	137
Sh ass are oci in (p ate rof d c its) om lo pan sse ies s o – f net	5									0	4
Ne t in com e ( los s)	302	199	3	47	28	5	26	9	103	(56 )	66 5
Ne to t in no com n-c e ( ont los rol s) a lin g i ttri nte bu tab res ts le	11									(4)	14
Ne t in com e ( los s) a ttri bu tab le
to Tev a	29 2	199	3	47	28	5	26	9	103	(60 )	65 1
EP S - Ba sic	0.2 6									0.3 3	0.5 9
EP S - D ilu ted	0.2 6									0.3 2	0.5 9

The non-GAAP diluted weighted average number of shares was 1,109 million for the three months ended September 30, 2021.

Non-GAAP income taxes for the three months ended September 30, 2021 were 17% on pre-tax non-GAAP income.

* Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.

					U. S. \$ a Th nd	sh ree M are on s in ths	m En illi on de d S s (e ept xce em	pt pe be r 3 r s ha 0, 2 re	02 am 0 ou nts )
	GA AP				Ex	clu ded fo	r n on -G AA P m	eas ure me nt					No n-G AA P
					Im ent			rel Co ate sts d t o
		Am of int pu ass ort ang rch iza ets ibl ase tio e d n	con set and tin tle Le gen lo me gal ss nts cie s	im Go pai odw rm ill ent	of pai ass liv lon rm ets ed g	exp Oth R& ens D er es	Re stru cos ctu ts rin g	reg fac tak act ula ilit en ion tor ies in s y	com Eq pen uit sat y ion	con Co sid nti era ng ent tio n	no item n-G Oth AA er s* P	item Oth er s
Ne t re ven ue s	3,9 78												3,9 78
Co st o f sa les	2,1 26	22 1						6	7		(2)		1,8 94
Gr oss pr ofi t	1,8 52	22 1						6	7		(2)		2,0 84
Gr oss pr ofi t	46 .6%												52 .4%
R& ma D rgi exp n ens es	25 8					21			5				23 3
S& M exp ens es	60 5	31							8				56 6
G& A e xp ens es	27 9								10		—		26 9
Oth er inc om e	(8)										—		(8)
Le and gal se lo ttle ss me nts
con tin gen cie s	21		21										—
Oth im er pai ass rm ets ent s,
res and tru ot ctu her rin ite g ms	(98 )				56		9			(17 9)	15		—
Int im ang pai ibl rm e a ent sse s ts	50 9				50 9								—
Go im odw pai ill rm ent	4,6 28			4,6 28									—
Op (lo era ss) tin g i nco me	(4, 342 )	25 1	21	4,6 28	56 5	21	9	6	30	(17 9)	14		1,0 25
Fin exp anc ens ial es, ne t	117											(12 4)	24 1
Inc tax bef om es ore e ( in los com s) e	(4, 45 9)	25 1	21	4,6 28	56 5	21	9	6	30	(17 9)	14	(12 4)	784
Inc om e ta xes	16											(11 7)	133
Sh net com ass (lo are sse oci in pan pr s)o ate ies ofi f d – t	(13 6)											(13 4)	(1)
Ne Ne no int attr t in t in n-c ere ibu com com sts ont tab e ( e ( rol le t los los lin o s) s) g	(4, 34 10 0)	25 1	21	4,6 28	56 5	21	9	6	30	(17 9)	14	(37 (6) 5)	652 15
Ne Tev attr t in ibu a com tab e ( le t los o s)	(4, 34 9)	25 1	21	4,6 28	56 5	21	9	6	30	(17 9)	14	(38 1)	63 7
EP EP S - S - D Ba ilu sic ted	(3. (3. 97) 97)											4.5 4.5 5 5	0.5 0.5 8 8

The non-GAAP diluted weighted average number of shares was 1,100 million for the three months ended September 30, 2020.

Non-GAAP income taxes for the three months ended September 30, 2020 were 17% on pre-tax non-GAAP income.

*

Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.

				U. S. \$ a	nd Ni sh ne are Mo s in nth m s E	illi nd on ed s (e Sep xce tem	pt be pe r 3 r s 0, 2 ha re 02 am 1	ou nts )
	GA AP				Ex clu ded fo r n on	-G AA P m	eas ure me nt				No n-G AA P
						Co sts
		Am ort iza tio n	Le gal	Im pai rm ent		reg rel ula ate d t tor o y
		of pu rch ase d	set tle me nts	of lon g		act ion s			Oth er
		int ass ang ets ibl e	con and tin gen lo ss cie s	ass liv ets ed	Re stru cos ctu ts rin g	fac tak ilit en ies in	com Eq pen uit sat y ion	con Co sid nti era ng ent tio n	no item n-G AA s* P	Oth item er s
Ne t re ven ue	11, 77 8										11, 77 8
Co st o f sa les	6,2 34	53 8				17	17		195		5,4 67
Gr oss pr ofi t	5,5 44	53 8				17	17		195		6,3 11
Gr oss pr ofi t m arg in	47 .1%										53 .6%
R& D exp ens es	72 3						14		5		704
S& M exp ens es	1,7 98	76					24		—		1,6 98
Oth G& A e er (in xp com ens es e) exp ens e	822 (73 )						31		(44 7 )		78 (29 5 )
Le gal se ttle me nts an d l oss
con tin gen cie s	113		113								—
Oth er ass ets im pai rm ent s,
Int res ang tru ibl ctu e a rin sse g a ts i nd mp ot air her me ite nt ms	29 22 5 7			29 106 5	96			(7)	32		— —
Op era tin g i nco me (lo ss)	1,6 38	61 3	113	40 1	96	17	86	(7)	194		3,1 53
Fin anc ial exp ens es, ne t	805									104	70 1
Inc om e ( los s) b efo re inc om e
tax es	833	61 3	113	40 1	96	17	86	(7)	194	104	2,4 52
Inc om e ta xes	23 5									(18 2)	41 7
Sh ass are oci in (p ate rof d c its) om lo pan sse ies s o – f net	(9)									(1)	(8)
Ne t in com e ( los s)	60 8	61 3	113	40 1	96	17	86	(7)	194	(79 )	2,0 42
Ne t in com e ( rol los lin s) a ttri bu tab le t o
no n-c ont g i nte res ts	32									(10 )	42
Ne t in com e ( los s) a ttri bu tab le t o
Tev a	57 6	61 3	113	40 1	96	17	86	(7)	194	(90 )	2,0 01
EP S - Ba sic	0.5 2									1.2 9	1.8 2
EP S - D ilu ted	0.5 2									1.2 9	1.8 1

The non-GAAP diluted weighted average number of shares was 1,109 million for the nine months ended September 30, 2021.

Non-GAAP income taxes for the nine months ended September 30, 2021 were 17% on pre-tax non-GAAP income.

*

Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.

				U.	S. \$ a nd Ni sh ne	are mo s in nth m s e illi nd on ed s (e	Sep xce tem pt be pe r 3 r s	0, 2 ha re 02 0 am ou nts )
	GA AP				Ex clu	ded fo r n on -G AA	P m eas ure	me nt				No n-G AA P
		Am ort iza tio	Le		Im pai rm ent		rel Co ula ate sts d t tor o
		of int pu ass ang rch ets ibl ase e d n	con set and tin tle lo me gal ss nts cie s	im Go pai odw rm ill ent	of ass liv lon ets ed g	Re stru cos ctu ts rin g	reg fac tak act ilit en ion ies in s y	com Eq uit sat y ion	con Co sid nti era ng ent tio n	no item n-G Oth AA er s* P	Oth item er s
Ne t re ven ue	12, 20 6		gen					pen				12, 20 6
Co st o f sa les	6,5 28	66 3					17	19		30		5,7 99
Gr oss pr ofi t	5,6 78	66 3					17	19		30		6,4 07
Gr oss pr ofi t m arg in	46 .5%											52 .5%
R& D exp ens es	704							14		3		68 7
S& M exp ens es	1,8 15	95						25				1,6 95
G& A e xp ens es	846							31		12		803
Oth exp er ens (in com e e)	(30 )									(3)		(27 )
Le gal se ttle me nts an d
los s c ont ing enc ies	10		10									—
Oth res im er pai tru ass rm ctu ets ent rin g a s, nd
oth er item s	40 4				40 8	82			(96 )	10		—
Int im ang pai ibl rm e a ent sse ts	1,2 78				1,2 78							—
Go odw ill im pai rm ent	4,6 28			4,6 28
Op (lo era ss) tin g i nco me	(3, 97 8)	75 8	10	4,6 28	1,6 86	82	17	90	(96 )	52	—	3,2 48
Fin net anc ial exp ens es,	56 5										(11 8)	68 3
Inc inc om om e ( e ta los s) b xes efo re	(4, 54 3)	75 8	10	4,6 28	1,6 86	82	17	90	(96 )	52	(11 8)	2,5 65
Inc om e ta xes	(14 7)										(58 3)	43 6
Sh com ass are oci in pan lo ate ies sse d – s o net f	(13 5)										(13 4)	(1)
Ne attr t in ibu com tab e ( le t los o s)
Tev a	(4, 26 1)	75 8	10	4,6 28	1,6 86	82	17	90	(96 )	52	(83 5)	2,1 30
Ne no int attr t in n-c ere ibu com sts ont tab e ( rol le t los lin o s) g	(12 1)										(17 4)	53
Ne t in com e ( los s)	(4, 140 )	75 8	10	4,6 28	1,6 86	82	17	90	(96 )	52	(1, 00 9)	2,0 77
EP S - Ba sic	(3. 78)										5.6 8	1.9 0
EP S - D ilu ted	(3. 78)										5.6 7	1.8 9

The non-GAAP diluted weighted average number of shares was 1,099 million for the nine months ended September 30, 2020.

Non-GAAP income taxes for the nine months ended September 30, 2021 were 17% on pre-tax non-GAAP income.

*

Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, such as certain accelerated depreciation expenses and inventory write offs, primarily related to the rationalization of our plants and other unusual events.

Non-GAAP Tax Rate

Non-GAAP income taxes in the third quarter of 2021 were \$137 million, or 17%, on pre-tax non-GAAP income of \$807 million. Non-GAAP income taxes in the third quarter of 2020 were \$133 million, or 17%, on pre-tax non-GAAP income of \$784 million. Our non-GAAP tax rate in the third quarter of 2021 was mainly affected by the mix of products we sold and interest expense disallowance.

Non-GAAP income taxes in the first nine months of 2021 were \$417 million, or 17%, on pre-tax non-GAAP income of \$2,452 million. Non-GAAP income taxes in the first nine months of 2020 were \$436 million, or 17%, on pre-tax non-GAAP income of \$2,565 million.

We expect our annual non-GAAP tax rate for 2021 to be between 17% to 18%, similar to our non-GAAP tax rate for 2020, which was 17%.

Off-Balance Sheet Arrangements

Except for securitization transactions, which are disclosed in note 10(f) to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, we do not have any material off-balance sheet arrangements.

Critical Accounting Policies

For a summary of our significant accounting policies, see note 1 to our consolidated financial statements and "Critical Accounting Policies" included in our Annual Report on Form 10-K for the year ended December 31, 2020.

Recently Issued Accounting Pronouncements

See note 1 to our consolidated financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There has not been any material change in our assessment of market risk as set forth in Item 7A to our Annual Report on Form 10-K for the year ended December 31, 2020.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Teva maintains "disclosure controls and procedures" (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that information required to be disclosed in Teva's reports filed or submitted under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to Teva's management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective.

After evaluating the effectiveness of our disclosure controls and procedures as of September 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, Teva's disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the quarter ended September 30, 2021, there were no changes in internal control over financial reporting that materially affected or are reasonably likely to materially affect Teva's internal control over financial reporting.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject to various litigation and other legal proceedings. For a discussion of these matters, see "Commitments and Contingencies" included in note 10 to the consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

ITEM 1A. RISK FACTORS

There are no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Unregistered Sales of Equity Securities

There were no sales of unregistered equity securities during the three months ended September 30, 2021.

Repurchase of Shares

We did not repurchase any of our shares during the three months ended September 30, 2021 and currently cannot conduct share repurchases or pay dividends due to our accumulated deficit.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

• 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
• 31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
• 32 Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *
• 101.INS XBRL Taxonomy Instance Document
• 101.SCH XBRL Taxonomy Extension Schema Document
• 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
• 101.DEF XBRL Taxonomy Extension Definition Linkbase Document
• 101.LAB XBRL Taxonomy Extension Labels Linkbase Document
• 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
• 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Date: October 27, 2021 By: /s/ Eli Kalif Name: Eli Kalif Title: Executive Vice President, Chief Financial Officer (Duly Authorized Officer)

82

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Kåre Schultz, certify that:

• 1. I have reviewed this quarterly report on Form 10-Q of Teva Pharmaceutical Industries Limited;
• 1. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
• 1. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
• 1. The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
  2. a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  3. b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  4. c. evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  5. d. disclosed in this report any change in the company's internal control over financial reporting that occurred during the company's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and
• 1. The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):
  2. a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
  3. b. any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.

Date: October 27, 2021

/s/ Kåre Schultz

Kåre Schultz President and Chief Executive Officer

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Eli Kalif, certify that:

• 1. I have reviewed this quarterly report on Form 10-Q of Teva Pharmaceutical Industries Limited;
• 1. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
• 1. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
• 1. The company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:
  2. a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  3. b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  4. c. evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  5. d. disclosed in this report any change in the company's internal control over financial reporting that occurred during the company's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and
• 1. The company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions):
  2. a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information; and
  3. b. any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.

Date: October 27, 2021

/s/ Eli Kalif

Eli Kalif Executive Vice President, Chief Financial Officer

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Teva Pharmaceutical Industries Limited (the "Company") on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Kåre Schultz, President and Chief Executive Officer of the Company, and Eli Kalif, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

• (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
  • (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: October 27, 2021

/s/ Kåre Schultz Kåre Schultz President and Chief Executive Officer

/s/ Eli Kalif Eli Kalif Executive Vice President, Chief Financial Officer